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ABSTRACT OF DISSERTATION

THE PREBIOTIC INULIN BENEFICIALLY MODULATES THE GUT-BRAIN AXIS
BY ENHANCING METABOLISM IN AN APOE4 MOUSE MODEL
Alzheimer’s disease (AD) is the most common form of dementia and a growing
disease burden that has seen pharmacological interventions primarily fail.
Instead, it has been suggested that preventative measures such as a healthy
diet may be the best way in preventing AD. Prebiotics are one such potential
measure and are fermented into metabolites by the gut microbiota and acting as
gut-brain axis components, beneficially impact the brain. However, the impact of
prebiotics in AD prevention is unknown. Here we show that the prebiotic inulin
increased multiple gut-brain axis components such as scyllo-inositol and short
chain fatty acids in the gut, periphery, and in the case of scyllo-inositol, the brain.
We found in E3FAD and E4FAD mice fed either a prebiotic or control diet for 4months, that the consumption of the prebiotic inulin can beneficially alter the gut
microbiota, modulate metabolic function, and dramatically increase scyllo-inositol
in the brain. This suggests that the consumption of prebiotics can beneficially
impact the brain by enhancing metabolism, helping to decrease AD risk factors.
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Chapter 1
1.1

Background

Dissertation Overview
Alzheimer’s disease (AD) is the most common form of dementia with age

being the greatest risk factor but with certain genetic differences also
dramatically increasing one’s risk of developing this disease. These include
having the Apolipoprotein 4 (APOE4) allele and Familial Alzheimer’s Disease
(FAD) gene mutations. Recently, the gut-brain axis, or bi-directional
communication between gut microbiota and brain, has become a topic of intense
investigation. Indeed, the gut microbiome, or the trillions of bacteria in the gut,
can be modulated to improve one’s health, including that of brain health. One
way to modulate the gut microbiome is by the ingestion of prebiotics, the nondigestible carbohydrates in certain foods that promote the growth of beneficial
bacteria. One such prebiotic is inulin, a prominently studied prebiotic found in
chicory root and other vegetables. We will test the hypothesis that modulating the
gut microbiome with the prebiotic inulin will potentially prevent AD-like symptoms.

1.2

Alzheimer’s Disease: Overview
AD is a chronic neurological disorder originating in the hippocampus and

frontal and temporal lobes and characterized by a progressive decline in one’s
mental capabilities and cognition [1]. AD is the most common form of dementia
with advanced age being the greatest risk factor [2]. As such, AD has become a
growing health concern for society as the prevalence of this disease has
concurred with the increasing age of the baby boomer population. Indeed, it is
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anticipated that the population greater than 65 years of age will double between
the years 2010 to 2050, according to the U.S. Census Bureau [3]. This is quite
worrisome as the incidence of AD increases exponentially after the age of 65,
and increases even more after the age of 90 [4]. With pharmacological
interventions primarily failing, new preventive measures need to be utilized to
prevent and delay the onset of this disease in those susceptible to AD [5].
Indeed, a recent study has indicated that preventative measures such as
exercising, eating a healthful diet, and cognitive training may be an effective way
to prevent AD [6].
AD has two primary hallmarks. These are the formation of amyloid β (Aβ)
plaques and neurofibrillary tangles (NFTs), or hyper phosphorylated tau. Usually,
Aβ deposition precedes the formation of NFTs with accumulation beginning in
the isocortical areas of the brain followed by the limbic and allocortical structures
and lastly, progressing to the subcortical structures and cerebellar cortex [7].
Further, Aβ is a 36-43 amino acid peptide cleaved from amyloid precursor
protein (APP) by the successive cleavage of β- and γ-secretases [7]. These form
intermediate soluble oligomers and insoluble β-sheet pleated amyloid fibrils that
are the primary components of extracellular Aβ plaques. These plaques may be
diffuse, amorphous wisps of amyloid without a central core not associated with
AD, or dense-core plaques, composed of a dense Thioflavin-S-(ThioS-) positive
core and are associated with the progression of AD. Dystrophic neuritis and
activated microglial cells and astrocytes also usually surround dense-core
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plaques and are most pronounced in the cerebral cortex and hippocampus of the
brain [7].
The second hallmark, tau, is an intracellular microtubule protein that
supports axonal transport via stabilization of microtubules. However, in AD, tau
is hyper phosphorylated and aggregates, forming NFTs. NFTs originate in the
medial temporal lobes and hippocampus with eventual spread to the neocortex
[7]. They have a spatiotemporal progression that is associated with the severity
of cognitive decline. Though generally thought of as the intracellular hallmark,
these tangles can become extracellular when neurons die. Aside from these two
primary AD hallmarks, other notable characteristics of AD include neuronal and
synapse loss and cognitive decline, ultimately leading to dementia [7].
The single greatest risk factor for AD is increased age [8]. However, other
risk factors include high blood pressure, hypercholesterolemia, Type-2 diabetes
(T2D), and the female gender. After the age of 75, females exhibit a 2-fold
greater risk of AD compared to men, perhaps due to lack of estrogen [8].
However, the greatest genetic risk factor that increases one’s risk of developing
AD is the apolipoprotein E4 (APOE4) allele, while other genetic risk factors
include the Familial Alzheimer’s Disease (FAD) genetic mutations [8].

1.2.1 Genetic Risk Factors
Genetic risk factors for AD include the FAD mutations. These are
mutations in the APP, presenilin 1 (PSEN1), and/or presenilin 2 (PSEN2) genes
that lead to early onset Familial Alzheimer’s Disease [9]. These mutations cause
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increased cleavage by γ-secretase and formation of the 42 amino acid Aβ
isoform, which aggregates more readily than the 40 amino acid form. As a
clinical diagnostic marker, the 42/40 amino acid ratio of Aβ can predict the age of
onset of AD [10].
The greatest genetic risk factor towards AD is the APOE4 allele. APOE is
a class of proteins essential for the transport and catabolism of triglyceride-rich
lipoprotein among certain cells and tissues. In fact, APOE is primarily
synthesized and secreted in the liver but is also produced in the brain, adrenal
glands, testis, and skin. It has a strong affinity for lipids and phospholipids and
may become lipidated through interactions with the cell surface or secretory
vesicles [11]. APOE has three isoforms in humans: APOE2, protective against
AD, APOE3, neutral towards AD, and APOE4, increases one’s risk of developing
AD. Notably, the allele frequencies vary considerably in the human population.
APOE3 is the most common at 77%, followed by APOE4 at 15%, and APOE2 at
8% of the population. Intriguingly, APOE2 and APOE4 only vary from APOE3 by
a single amino acid substitution in this 299-amino acid protein. Indeed, APOE2
contains a cysteine at 112 and 158, APOE3 contains a cysteine at 112 and an
arginine at 118, and APOE4 contains arginine at both 112 and 158 [12].
However, this substitution has a profound effect on the individual towards the
development of AD, cerebral amyloid angiopathy, amyloid deposition in blood
vessels, and recovery from cerebral trauma [11].
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1.2.2 APOE4 Risk Factors
Despite APOE4 and APOE3 only being different by a single amino acid,
APOE4 can increase one’s risk of developing AD dependently and
independently of Aβ. Dependently of Aβ, APOE4 may increase AD risk because
of the differences in the affinity for Aβ due its lipid-binding domain [13]. This lipidbinding domain is located on the C-terminus of APOE, whereas the N-terminus
houses the amino acid differences between APOE3 and APOE4. This suggests
the C- and N-terminus regions interact affecting what APOE3 and APOE4
preferentially bind, including the isoform differences displayed when binding to
the Aβ peptide. Indeed, APOE4 binds more rapidly to Aβ and even appears to
enhance zinc- and copper-induced Aβ aggregation compared to APOE3 [14].
However, this binding of APOE4 to Aβ may depend upon its lipidation state
including whether or not it is purified, lipid-poor, reconstituted with HDL lipids, or
originated from astrocytes, cerebral spinal fluid (CSF), or serum. In general, it is
also thought that APOE4 is less lipidated than APOE3 with an increased chance
of being in an intermediate molten globule state, an unstable form [15]. This
would provide less surface area for Aβ to interact with. Further confirming this in
one study using mice, soluble APOE4/Aβ complex levels were decreased and
had less stability compared to APOE3. It was also discovered that oligomerized
Aβ was increased in APOE4 mice compared to APOE3 mice [16]. However, the
APOE4 may not only complex with Aβ more effectively than APOE3, as
previously mentioned, but also appears to decrease Aβ clearance from the brain,
leading to increased plaque formation [11]. Overall, it appears the APOE4/Aβ
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complex is less lipidated and stable than that of APOE3 in vitro, potentially
increasing oligomerized Aβ levels but decreasing Aβ clearance and thus,
increasing the risk of AD.
Aβ-independent mechanisms by which APOE4 increases one’s risk of AD
include inducing synaptic and cholinergic deficits, behavior dysfunction, and
impairment of GABAergic interneurons. However, the primary cause of APOE4
related AD deficits might be via fragmentation from proteolytic cleavage that may
originally be prompted by brain stressors or injury [11]. Indeed, APOE4 is more
susceptible to proteolytic cleavage than APOE3 [17]. These carboxyl-terminaltruncated fragments enter the cell, wreaking havoc on organelles including that
of tau and other cytoskeletal components. They have even been demonstrated
in vitro to increase the formation of neurofibrillary tangles and appear to lead to
mitochondrial dysfunction. Our lab has previously demonstrated in APOE4
mouse models that cerebral glucose metabolism is decreased [18] and these
truncated fragments may be one potential cause of this in APOE4 allele carrier.
Another notable experiment in human studies found that APOE4 allele carriers
had decreased cerebral blood flow (CBF) before AD-like symptoms occurred
[19]. One reason this may potentially occur was explained in a study
demonstrating that APOE4 leads to increased blood brain barrier (BBB)
permeability via activation of the Cyclophilin A (CypA)-Nuclear Factor-κ-B
(NFκB)-Metalloproteinase 9 (MMP-9) pathway in pericytes in the BBB [20]. The
APOE4 allele promotes this inflammatory pathway by inhibiting low-density
lipoprotein receptor-related protein 1 (LRP1) function, which maintains CypA
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levels. In contrast, APOE3 normally stimulates LRP-1 activity. Thus, APOE4
increases the pathway in which MMP-9 leads to tight junction barrier degradation
via decreased protein expression of ZO-1, occludin, and claudin, basement
membrane degradation, increased BBB permeability, and decreased CBF [20].
Collectively, the APOE4 allele can increase one’s AD risk through mechanisms
dependent and independent of Aβ.

1.2.3 APOE4 on Host Metabolism
Carriers of the APOE4 allele also appear to have an altered metabolism.
Indeed, APOE4 allele preferentially binds to large very low-density lipoprotein
cholesterol (VLDL) particles and the APOE genotypes account for interindividual
differences in lipid and lipoprotein levels [21]. The allele is even associated with
a less desirable lipid profile that includes increased low-density lipoprotein
cholesterol (LDL-C) levels and risk for coronary heart disease [22]. The APOE4
allele also appears to play a role in glucose metabolism where APOE4 carriers
have decreased cerebral metabolic rate of glucose, even in young adults [23]. In
an AD mouse model utilizing the APOE4 allele, mitochondrial dysfunction began
as early as 3-months in the mice [24]. Further in an AD mouse model utilizing the
APOE4 allele and a mutation in APP, the APOE4 mice had greater impairment
of insulin signaling compared to the APOE3 mice [25]. Another study even
suggested that the APOE4 allele may interact with the insulin receptor less than
that of the APOE3 allele [26]. Next, other alterations in the brain have also been
found such as in one study by Johnson et al. that found APOE4 mice to have
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alterations in hippocampal metabolites involved in purine, glutamate,
glycerophospholipid (GPL), and pentose phosphate pathway metabolism [27].
Collectively, the APOE4 allele appears to lead to mitochondrial dysfunction and
deleterious alterations in glucose and lipid metabolism.

1.2.4 APOE Mouse Models
One of the more effective ways of understanding the isoform effects
caused by the APOE4 and APOE3 alleles on AD pathology is by using APOE
transgenic mouse models [28]. In their history, APOE knock out models were
initially utilized in an attempt to understand the effect of APOE in the brain.
However, due to the differences in mouse and human APOE, this had severe
shortcomings for translating these studies to humans. Indeed, the homology of
mouse and human APOE is only 70%. Thus, to expand this research, mouse
models that expressed APOE specifically in glia or neurons through
heterologous promoters were utilized. These include glial fibrillar acidic protein
(GFAP, GFAP-APOE) and neuron-specific enolase (NSE, NSE-APOE).
Unfortunately, heterologous promoters are not as well-regulated as endogenous
promoters for a few reasons: protein expression and copy number of the
transgene is not as well controlled, and evidence suggests glia, not neurons,
primarily express APOE. Thus, mouse models using knock-in, or target
replacement (TR), of human APOE utilizing endogenous promoters for
expression of APOE were generated. APOE-TR models have glial cells that
express human APOE at physiological levels, replacing mouse APOE, a huge
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advantage over previous models. Next, APOE-deficient and APOE-TR models
were crossed with those that express human FAD mutations, including mutations
in APP and/or PS1, with the goal of examining the effects of various human
APOE isoforms on Aβ deposition [28]. The human FAD models are generally
designated Aβ-Tg and include PDAPP (APPV717F), J9 (PS1M146V,L286V, APPV717F),
and 5xFAD (APPK670N,M671L,I716V,V717I, PS1M146V,L286V), the latter having a more
rapid onset of AD pathology than the two former. Typically, Aβ-Tg models
develop plaque formation by 6-months of age; however, 5xFAD mice develop
plaques by 2-months of age. When target replacement human APOE3 or
APOE4 is added to 5xFAD mice (EFAD), plaque formation is delayed by 4
months. Due to this delay in plaque deposition, the EFAD model offers an easier
and more tractable ability to analyze plaque accumulation in the presence of
human APOE alleles and the progression thereof. The EFAD model is also
advantageous for studying markers related to AD, analyzing Aβ plaque formation
via regional and temporal comparisons in the brain, and using interventions that
may be more translatable to humans than previously mentioned AD mouse
models [28].
The mouse model that is the focus of this dissertation is the EFAD mouse
model (E3FAD and E4FAD) that utilizes mice with the C57BL/6 background that
are a cross of transgenic mice that overexpress human Aβ via 5 FAD (5xFAD)
mutations and mice that express either the target replacement human APOE3 or
APOE4 gene. This recent model was developed by Dr. Mary Jo LaDu in 2012
[29]. The first study featuring this model described the synergistic effects of
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APOE4 and Aβ. In mice with FAD mutations, amyloid deposits develop as early
as 2-months of age [30]. However, the addition of APOE4 delayed amyloid
deposition [31]. This holds true in this E4FAD model as the mice in this study
demonstrated changes in Aβ buildup starting between 2- to 6-months of age,
with E4FAD have greater total Aβ levels and Aβ42 compared to E3FAD mice.
Specifically, total Aβ42 was greater in the hippocampus and cortex of APOE4
mice compared to APOE3 but levels remained the same in the cerebellum. Next,
E4FAD mice had significantly greater plaque deposition than E3FAD mice in the
frontal cortex and subiculum at 4-months of age and in the frontal cortex at 6months of age. Interestingly, the E4FAD mice had significantly greater amounts
of dense-core plaques while the E3FAD mice had more diffuse plaques. APOE4
levels were significantly lower than APOE3 in the cerebellum at 4-months of age,
the cortex at 2-, 4-, and 6-months of age, and the hippocampus at 2- and 4months of age. Overall, APOE levels were greatest in the cortex and
hippocampus, regions susceptible to Aβ deposition, and lowest in the
cerebellum, a brain region resistant to Aβ, with APOE4 levels lower than APOE3
in each brain region at each time point. Quite importantly, soluble Aβ42 and
soluble oligomeric Aβ levels, both associated with AD progression, were higher
in the APOE4 mice compared to the APOE3 mice at 6-months of age. Based on
these findings, the authors concluded that in the E4FAD mice, the decreased
total APOE4 but increased Aβ42 levels is indicative that APOE4 promotes Aβ
accumulation in the hippocampus and cortex. However, this is due to the
function of APOE4, not the quantity thereof [29].
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Other studies using the EFAD transgenic mice have found additional
genotype effects. Rodriguez et al. found that E4FAD mice have more prominent
plaques via Aβ staining than the E3FAD mice along with more dense plaques in
the subiculum. Interestingly, the E4FAD mice had much greater cortical levels of
IL-1β, a proinflammatory cytokine, in the cortex compared to E3FAD mice.
E4FAD mice also exhibited increased measures of microglia reactivity and
dystrophy in the cortex along with a genotype effect on the number of microglial
cells surroundings plaques. Further, E4FAD mice had significantly greater
average microglial cells surrounding plaques compared to APOE3. Collectively,
this study showed that E4FAD mice have increased microglial and cytokine
activation compared to E3FAD mice [32].
EFAD mice have displayed genotype differences in cognition. Liu et al.
demonstrated that female E4FAD mice at 2-, 4-, and 6-months of age displayed
an intensified age-dependent decline in the Morris water maze test compared to
E3FAD mice, indicative of diminishing long-term reference memory, spatial
learning, and working memory. The E4FAD also demonstrated an agedependent decline in the Y-maze, unlike the E3FAD mice, indicative of decaying
spatial recognition memory. Similar to other aforementioned studies, the total
APOE levels were decreased in E4FAD mice compared to E3FAD. Next, the
E4FAD mice in this study also have reduced post-synaptic protein levels, Nmethyl-D-aspartate receptor (NMDAR) levels, and brain-derived neurotropic
factor (BDNF) levels at 6-months of age, which likely contribute to the cognitive
deficits seen in E4FAD mice [33].
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Other studies in E4FAD and E3FAD mice demonstrate that female
E4FAD mice had greater cerebral cortex microbleeds and hemosiderin, an ironstorage compound that is often formed after bleeding, than male E4FAD mice.
The authors looked for similar effects in human APOE4 patients but found no
sex differences [34]. Although interesting, there may be limitations to the EFAD
mouse model in its translatability to humans. One limitation of this model is the
lack of development of tau pathology typically seen in AD. However, Zhou et al.
demonstrated that E4FAD mice had greater site-specific tau phosphorylation,
potentially due to calpain-CDK5 signaling, compared to E3FAD mice [35].
Although the tau phosphorylation is more restrained in this study then typically
seen in AD, it is notable that APOE4 and/or FAD mutations lead to increased tau
phosphorylation.
Next, Teter et al. demonstrated in a recent study that E4FAD mice,
compared to E3FAD mice, had reduced miR146a, a microRNA in the brain and
plasma that is increased in AD patients and helps regulate the inflammatory
process by down regulating NFκB. Thus, it acts to decrease inflammation. The
FAD mutations increase miR146a, however, the APOE4 allele appears to inhibit
this process compared to the APOE3 allele, increasing the inflammatory
process. Here, we see genotype differences in the inflammatory process
independent of Aβ in an EFAD mouse model [36]. Female E4FAD mice were
treated with epidermal growth factor (EGF), which prevented cognitive decline,
decreased microbleeds, and limited cerebrovascular dysfunction. Interestingly,
the female E4FAD mice had greater cognitive impairment, lower EGF serum
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levels, and greater microbleeds than their male counterparts. It is unclear why
E4FAD female mice have such an exacerbated response, but the authors
attribute this to increased extracellular Aβ exhibited in female mice and/or an
enhanced inflammatory response in the brain [37]. Finally, a recent study by
Abdullah et. al. investigating the effect of the APOE genotype on blood
phospholipids found that E4FAD mice had a greater plasma arachidonic
acid/docosahexaenoic acid (DHA) ratio, a ratio associated with increased
inflammation, compared to the E3FAD mice. This was further confirmed in
human subjects, where this ratio preceded the diagnosis of AD. This is yet
another marker of interest that the APOE4 allele may deleteriously impact AD
risk [38].
Although the EFAD model is fairly new, a variety of studies have been
published indicating that the combination of APOE4 and FAD mutations leads to
AD through multiple mechanisms. However, mechanisms that originate from the
gut impacting one’s risk of developing AD has recently become of intense
interest. The APOE allele has actually been implicated to impact the gut
microbiome. In fact, the APOE4 allele actually appears to be protective against
diarrhea, enteric infections, and malnutrition in children in the developing world
such as in Brazil [39]. While these effects may not be as much of an issue in first
world countries such as the United States, the APOE4 allele may save the lives
of children in developing countries such as Brazil. However, they will still be at
an increased risk of dementia as they age. Further, studies in AD mouse models
have found alterations in amyloid pathology. Indeed, APP/PS1 transgenic mice
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demonstrated an increase in amyloid pathology and immune reactivity in the
intestines compared to wild-type mice [40]. In another study using this same
APP/PS1 transgenic mouse model, Harach et al. found that germ-free (GF) mice
had decreased amyloid pathology in the brain compared to mice that did have a
gut microbiome [41]. Based off of this, certainly the APOE allele and FAD
mutations play a role in the gut microbiome, although much has yet to be
learned.

1.3

Gut Microbiome: Overview
The gut microbiome, or the trillions of bacteria that inhabit our gut, play

a profound and ever-growing role on the host’s health. The microbiome
contains over 1,000 bacterial species, though it may actually be much higher
than this, each exerting their own specific effects. However, there are just a
few primary bacterial phyla: Firmicutes, Bacteroidetes, Actinobacteria,
Verrucomicrobia, and Proteobacteria [42]. Interestingly, the ratio of Firmicutes
to Bacteroidetes has become a well-known biomarker of certain diseases with
an increased Firmicutes to Bacteroidetes ratio present in obesity. This may
even lead to excessive low-grade inflammation [43]. Confusingly, in
inflammatory bowel disease (IBD) patients, an increased and decreased
Firmicutes to Bacteroidetes ratio has been observed [44, 45]. Importantly, this
ratio is altered with age. Although not unanimous in the literature as diet and
environment play a profound role, children typically have decreased amounts
of Firmicutes, and thus a decreased Firmicutes to Bacteroidetes ratio, but this
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increases dramatically as one enters into adulthood. However, after adulthood
and into elderly status, a decreased Firmicutes to Bacteroidetes ratio is
exhibited [46]. The mechanisms behind these changes are not currently well
understood.
Certain bacterial species have been demonstrated to have important
effects on the host, beneficial and deleterious. For example, Akkermansia
muciniphila has been demonstrated to increase insulin sensitivity but decrease
fat mass and inflammation [47]. In contrast, other bacterial species such as
Clostridium difficile, or C. diff, an opportunistic bacterium that when in excess,
produces two exotoxins, A and B, can cause diarrhea. Elderly hospital patients
are particularly susceptible and deaths are not uncommon [48]. Considering
there are over 1,000 bacterial species, the aforementioned two bacterial
species are just the tip of the iceberg and thus, more research needs to be
conducted to elucidate the effects of each.
The gut microbiota impacts host metabolism as demonstrated in germfree (GF) mice studies. In one GF mice study, the GF mice have decreased
body fat compared to control mice despite eating more calories [49]. This is
indicative of the gut microbiota impacting energy harvest from food and
subsequent fat storage. GF mice are even protected from insulin resistance
[50] but when the feces of control mice were inserted into germ-free mice, an
increase in body fat and insulin resistance ensued [51]. This may partly be due
to the differences in the development of the gut epithelium with control mice
having more small intestinal villi, promoting increased energy harvest. Further,
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alterations in gene expression in the liver and adipose tissue are present
between GF and control mice, altering lipid and mitochondrial metabolism [52,
53]. The alterations in fat storage may also be due to differential regulation of
the intestinal expression of fasting-induced adipose factors (FIAF). FIAF
inhibits lipoprotein lipase (LPL) in adipose tissue and activates the breakdown
of triacylglycerol into fatty acids, used by muscle and adipose tissue. GF mice
had elevated FIAF relative to control mice, leading to increased fat mass in
control mice [51]. Similar studies have been performed in humans where fecal
matter was transferred from lean donors to individuals with metabolic
syndrome. One study found that the individuals with metabolic syndrome had
increased microbial diversity and improved insulin sensitivity after the fecal
donation [54]. Taken together, the gut microbiota regulates glucose and lipid
metabolism while ultimately impacting fat mass and body weight.
Next, the gut microbiota synthesizes metabolites that affect host
metabolism. This includes short chain fatty acids (SCFAs) and bile acids,
among others. SCFAs are used extensively as an energy source for colonic
cells as well as a ligand for G-protein coupled receptors (GPR), including
GPR41 and GPR43, in many different tissues. Activation of these GPRs may
help reduce body weight and improve insulin sensitivity in liver and muscle [51,
55]. One potential mechanism is increased secretion of anorexigenic
hormones such as glucagon like peptide-1 (GLP-1) and peptide YY (PYY) via
GPR signaling [56]. Indeed, these hormones are thought to beneficially impact
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glucose metabolism [57, 58] and by working in the hypothalamus, decrease
appetite and thus, food intake [59].
The gut microbiota influences bile acid metabolism and thus impacts the
absorption of dietary lipids and fat-soluble vitamins. The primary bile acids
include cholate (CA) and chenodeoxycholate (CDCA), which are synthesized
in the liver. However, bile undergoes modifications before release into the
intestines via conjugation by glycine or taurine, boosting their function.
Although 95% of bile acid is reabsorbed by the ileum and returned to the liver,
the rest is converted into secondary bile acids by the gut microbiota [60]. The
secondary bile acids include deoxycholic acid (DCA) and lithocholic acid (LCA)
and have been demonstrated to decrease weight gain and serum cholesterol
[61]. In another study, taurine-conjugated DCA and CDCA were associated
with insulin resistance in nondiabetic individuals [62]. Although not particularly
well understood, bile acids may impact glucose metabolism through the
nuclear farnesoid X receptor (FXR) [63], explored next.
The production of bile acids is regulated by negative feedback inhibition
via the FXR [64], which the gut microbiota impacts. Indeed, the gut microbiota
has been demonstrated to cause diet-induced obesity via FXR signaling.
Further, Parseus et al. found the microbiota to increase adipose tissue
inflammation and hepatic expression of genes involved in lipid uptake [65]. It
has also been demonstrated that treatment with an FXR agonist increased
insulin sensitivity [66]. Interestingly, the activation of FXR by bile acids may
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even impact the immune system via increased expression of inducible Nitric
Oxide Synthase (iNOS) and IL-18 [67].
The gut microbiota has a profound effect on the immune system. One
reason is due to SCFAs activation of GPRs, namely GPR43, impacting the
immune system by regulation of colonic regulatory T-cells [68]. They have also
been demonstrated to increase IL-10, an anti-inflammatory cytokine [69],
suppress NF-κB and IL-2, regulate neutrophils [70], and suppress cytokine
production by monocytes [71]. Quite interestingly, SCFAs even impact the
brain by decreasing BBB permeability [72] and by regulating microglia maturity
[73]. However, the SCFAs are not the only metabolites produced by the gut
microbiota that impact the immune system. Indeed, aromatic amino acids such
as tryptophan can be metabolized to, for example, indole 3-propionic acid
(IPA). IPA is metabolized by the microbial species Clostridium sporogenes [74]
and can act as a ligand for the pregnane X receptor (PXR). Through PXR, IPA
can induce an increase in junctional protein mRNA expression while
decreasing TNF-α [74], leading the host to better intestinal health and
decreased inflammation.
Another way the gut microbiome interacts with the immune system is
through lipopolysaccharide (LPS), an endotoxin from the outer cell membrane
of Gram-negative bacteria, which can enter the circulation when a leaky gut is
present in the host. Leaky gut is the increased permeability of the intestinal
wall leading to low-grade inflammation and in extreme cases, sepsis [75].
Upon LPS entering the circulation, it can reach the liver or adipose tissue and
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initiate an innate immune response. This response includes the activation of
CD14 in the macrophage, activating toll-like receptor 4 (TLR4), which then
activates NF-κB and activator protein 1 (AP-1)[76]. Furthermore, circulating
endotoxin levels have also been linked to increased TNF-α and IL-6 in
adipocytes [77]. Interestingly, this deleterious alteration in immune function
may also lead to metabolic dysfunction. Indeed, Cani et al. demonstrated that
continuous subcutaneous infusion of LPS in mice leads to hyperglycemia and
insulinemia, weight gain, increased markers of inflammation, and liver insulin
resistance [78]. Importantly, LPS has also been demonstrated to increase
inflammation in the brain via activated microglia and increased expression of
TNF-α, Monocyte Chemoattractant Protein (MCP-1), IL-1β, and NF-κB [79].
Clearly, the production of metabolites by the gut microbiome has a deep
impact on the host immune system, even in the brain.

1.4

Gut-Brain Axis
The gut-brain axis (GBA) is the bi-directional communication between the

gut and the brain. Although a fairly new development in research, a few methods
of communication between the gut and brain have been identified. One such is
through the SCFAs butyrate, acetate, and propionate, which are produced by
certain bacterial species such as Bacteroides and Roseburia inulinivorans [80].
Specifically, butyrate has been demonstrated to prevent inflammatory responses
via NFκB inhibition in murine N9 microglia, hippocampal slice cultures [81], and
HT-29 cells [82]. Butyrate also affects BBB permeability [72] and along with
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propionate, improves glucose sensitivity and body weight control via gut-brain
neural circuits [83]. Further, excess acetate levels caused by an altered gut
microbiota were demonstrated to lead to obesity via the microbiome-brain-β cell
axis [84]. Another form of communication in the GBA is through tryptophan
metabolites. One example is indole propionic acid (IPA), which has been
demonstrated to inhibit Aβ fibril formation in neurons and neuroblastoma cells
[85]. Another tryptophan metabolite is serotonin, a neurotransmitter in the brain
and enteric nervous system (ENS). Interestingly, 95% of serotonin is produced
by ENS neurons and gut mucosal enterochromaffin cells [86]. In the gut and
periphery, serotonin impacts GI secretion and motility [87]. Additionally, the gut
microbiota can communicate through neural pathways such as through the ENS
and importantly, vagus nerve [88]. In fact, the vagus nerve appears, at least in
part, to be responsible for central GABA receptor expression, anxiety and
depression-like behavior, and corticosterone response [88]. In another study, the
reduction of anxiety by the probiotic Bifidobacterium longum was absent in mice
without a vagus nerve [89]. Next, numerous neurotransmitters that are produced
by enteroendocrine cells (EECs) in the GI tract that are stimulated by gut
microbial taxa or by-products thereof are also able to potentially impact the brain
[90]. This includes peptide YY, neuropeptide Y (NPY), and cholecystokinin.
Finally, another GBA communication pathway involves immune signaling [91].
Indeed, the gut microbiota is a very important immune organ that can impact the
brain. Notably in this communication pathway, consumption of the probiotic
Bifidobacterium infantis 35624 was found to enhance IL-10 in the periphery of
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humans [92]. Meanwhile, when GF mice are given commensal bacteria,
increases in Treg and IL-10 occur [93]. Importantly, it is thought that certain
immune cells can generate neurotransmitters that can signal to the brain and
even influence behavior [91]. An example of this in one study in mice found that
Mycobacterium vaccae activated the peripheral immune system, which went on
to stimulate serotonergic neurons of the dorsal raphe nucleus of mice, increasing
serotonin metabolism [94]. The study further proposed this was an important part
of mood regulation. Collectively, the GBA and its various communication
pathways play a pivotal yet sparsely explored role in the health of an organism.
We believe this may be an exciting venue of research with the goal of preventing
neurological diseases such as AD.

1.5

Prebiotics: Overview
To beneficially modulate the gut microbiota, an individual could consume

prebiotics. Prebiotics are the non-digestible portion of food that stimulates the
growth of beneficial bacteria. Although the exact definition of prebiotics varies,
Bindels et al. proposed this definition: “a non-digestible compound that, through
its metabolization by microorganisms in the gut, modulates composition and/or
activity of the gut microbiota [95].” For clarity, these classifications must be met
for a compound to be considered a prebiotic: digested by gastric enzymes in the
upper gastrointestinal (GI) tract, stimulate the growth of certain beneficial
bacteria, and fermented in the colon to produce metabolites such as SCFAs.
Specific prebiotics include resistant starch, oligosaccharides, and inulin.
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Prebiotics are, in general, non-digestible carbohydrates, or fiber, found in foods
such as fruits, vegetables, whole grains, and legumes. Whole foods typically
contain a mixture of insoluble and soluble fiber. Insoluble fiber does not dissolve
in water, is minimally fermented, but promotes regular bowel movements and
prevents constipation. On the other hand, soluble fiber forms a gel in water, can
be fermented into beneficial metabolites such as SCFAs, decreases cholesterol,
and regulates blood glucose. However, the benefits of soluble and insoluble often
overlap [96]. Different kinds of prebiotics include oligosaccharides, resistant
starch, inulin, etc. that are fermented by beneficial bacteria into SCFAs and other
metabolites, producing many of their advantageous effects. Other benefits
include improved gut barrier function, reduced colonies of pathogenic bacteria,
decreased risk of CVD, promotion of weight loss, beneficial modulation of the
immune system, enhanced mineral absorption, promotion of regular bowel
movements and intestinal health, cancer prevention, and reduced cholesterol
[97]. Although literature on prebiotics in regard to the GBA is scarce, prebiotics
have been demonstrated to elevate central BDNF, levels of which decrease
according to AD severity [98], and N-methyl-D-aspartate receptor (NMDA) [99],
but reduce waking cortisol levels in human subjects [100]. Collectively, prebiotics
have a vast array of benefits to the host and are easy to consume, making it an
ideal nutritional intervention in the fight against neurological disorders such as
AD.
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1.5.1 Inulin
For our project, we will use the prebiotic inulin, a soluble dietary fiber and
member of the fructans group, due to its well-documented ability to increase
SCFA production and increase Bifidobacterium bacterial populations [101].
United States citizens ingest 1-4g of inulin-type fructans (ITFs) per day,
considerably less than the 3-11g eaten by Europeans [102]. To be an ITF, a β-(21)-fructosyl-fructose glycosidic bond anywhere from 2 to 60 units long must be
present, giving inulin its ability to resist gastric enzymes in the upper GI, only to
be later fermented in the colon [101]. Notably, only gastrointestinal side effects
have been reported with inulin consumption including diarrhea, abdominal
rumbling, bloating, cramping, and excess flatulence. However, these effects are
generally seen in intakes greater than 40g per day, although individual variation
exists. A daily dose of 2.5-10g per day in humans is recommended to promote a
healthy gut microbiota [103].
Inulin is derived from the chicory root but is also found in garlic, onions,
artichoke, and in processed foods as a functional fiber. For food application,
when adding inulin, health claims can be made on the product, potentially
persuading consumers to eat the food for added health benefits. Inulin can also
be used to replace fat or sugar as inulin can be processed to have a similar taste
and/or texture [101].
ITFs include inulin, oligofructose, fructooligosacchardies (FOS), and
bifidogenic oligo- or polysaccharide chains. The latter of which are more derived,
smaller molecules. A way to classify these types is by their degree of
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polymerization (DP) [101]. For example, inulin has not undergone extensive
processing and is generally greater than 10 DP. However, oligofructose is less
than 10 DP and has undergone partial hydrolysis with all long chain ITFs
removed. Finally, FOS are very short chain inulin type fructans that are produced
from sucrose. Unfortunately, the literature can vary on classifying the types of
inulin by DP, so one should be careful when looking to specifically identify ITFs.
Further, the DP of ITFs also determines the location they will exert their effects. If
the product has a lower DP, it will exert effects towards the proximal colon, while
less derived, higher DP ITFs will exert effects in the distal colon. In the colon,
these ITFs are fully metabolized into carbon dioxide, hydrogen, SCFAs, lactate,
and other metabolites. This fermentation also makes the colon more acidic,
thought to be advantageous for the growth of beneficial bacteria, along with
increasing fecal content size. Finally, ITFs do indeed affect the gut microbiota.
Although not entirely conclusive due to differences in the type of inulin used in
the literature and individual differences, ITFs stimulate Bifidobacteria, increasing
its bacterial biomass. Indeed, Bifidobacteria can consume non-digestible
carbohydrates as energy sources such as ITFs. This genus contains at least 51
different species that have numerous beneficial effects including production of B
vitamins, maturation of immune system, protection of the gut barrier and
pathogens, and production of SCFAs [104]. When examining the literature, one
human study found that 20g of inulin was given for 8 days, and then ramped up
to 40g a day for another 10 days. This dietary regimen produced significant
increases in Bifidobacteria, whereas Enterococci and Enterobacteriaceae were
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decreased. However, effects of ITFs on bacterial species other than
Bifidobacteria are inconclusive at this time. In a recent study by Vandeputte et al.
in human subjects, inulin was found to alter bacterial abundance at the genuslevel via increased Bifidobacterium and Anareostipes but decreased Bilophila
[105]. Notably, some evidence supports a dose-dependent response to
increasing levels of inulin intake although this may depend on the state of the
host and variation in their gut microbiota prior to treatment with inulin [101].
Inulin is well known in the literature in both human and animal models and,
despite some inconsistencies, has time and time again produced beneficial
effects, making it quite possibly the most studied and verified of all prebiotics.
Indeed, inulin has been suggested to help with constipation in elderly females by
increasing stool frequency and making them softer [106], while other studies
have not demonstrated notable effects [103]. Similarly, inulin has been
demonstrated, albeit inconsistently, to reduce total cholesterol, LDL-cholesterol,
VLDL-cholesterol, and triglycerides in dyslipidemic and obese subjects [107]. In a
recent meta-analysis examining the effect of ITFs on blood lipids and glucose
levels in humans that were healthy, dyslipidemic, obese, and T2D patients, ITFs
were demonstrated to decrease LDL across all groups. However, ITFs
decreased fasting insulin and increased HDL only in certain T2D subgroups. The
authors attribute the latter to the differences in the gut microbiota and
pathological state of the subjects, e.g. T2D patients have increased blood
glucose and lipids. Nevertheless, this meta-analysis does provide compelling
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evidence that ITFs can indeed beneficially impact blood lipid profiles and
glucose.
In animal models, ITFs have also been demonstrated to have anticarcinogenic effects. Indeed, supplemented inulin has demonstrated anticarcinogenic effects in one study using mice and rats that were induced with
colon cancer using azoxymethane and dextran sulfate sodium (AOM/DSS). In
mice, the group fed the inulin-like fructans had decreased intestinal polyps and
decreased markers of inflammation such as TNF-α. Even more interesting, the
inulin groups had increased bone densitometry in their femur and vertebra in a
separate cohort of rats. However, serum calcium levels were not different [108].
Nevertheless, inulin has demonstrated anti-carcinogenic and anti-inflammatory
effects in the colon. The inconsistencies in the literature may be due to amount of
inulin given in each study.
Specific doses of inulin in animal models have varied but for the most part,
show benefits. In one of the more extreme cases, Parnell et al. fed 8-week-old
male lean and obese rats 0, 10%, or 20% of a 1:1 inulin and oligofructose mix for
10 weeks. The primary finding of this study was that the prebiotic fed groups had
decreased serum cholesterol and a reduction in liver triacylglyceride (TAG)
buildup compared to the obese control rats. A dose-response effect was not
observed but the authors suggest the 10% dose may be more beneficial.
Notably, these effects were not seen in the lean mice [109]. Another study also
used the 10% dose with an inulin fiber product called Orafti Synergy to test the
ability of rats to absorb iron and magnesium after being exposed to omeprazole,
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which inhibits passive magnesium transport and absorption. The results revealed
that inulin was able to restore calcium transport in the omeprazole treated rats,
but not magnesium, compared to the control group. As a side note, levels of
butyrate in the cecum and colon were also increased compared to the control
group [110]. Similar findings have been found in humans, with one study in
young healthy men demonstrating inulin to increase calcium absorption and
balance. However, the absorption of magnesium, iron, and zinc were not altered
[111].
In one study similar to the present dissertation project, Weitkunat et. al.
looked at the effects of a 10% inulin and 10% cellulose diet in gnotobiotic
C3H/HeOuJ mice colonized with a human microbiota, comprised of 8
represented bacteria, for 6 weeks. Firstly, the cellulose diet had significantly
greater fecal bulk and energy than the inulin group and thus, the inulin group had
10% higher digestibility. However, the calculated energy assimilation was not
different. This was apparent as the body weight and composition in the two
groups was also not different. Nor was liver weight or epididymal white adipose
tissue (eWAT). In regard to the gut microbiota, the inulin group had an increased
total bacterial cell number due to the increase in 6 of the 8 members of their
human gut microbiota. These included Anaerostipes caccae, Bacteroides
thetaiotaomicron, Bifidobacterium longum, Blautia producta, Clostridium
butyricum, and Clostridium ramosum. Importantly, the inulin group also had
significantly increased amounts of the SCFAs acetate, propionate, and butyrate
in the cecum and significantly increased acetate and propionate in the plasma of
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the portal vein. Inulin also altered liver genes associated with lipogenesis and
fatty acid elongation. Finally, the inulin group exhibited a decreased ratio of
omega-6 to omega-3 in the plasma, liver, and eWAT. Together, the authors
believe these results signify that inulin may alter and decrease hepatic lipid
metabolism while the decreased omega-6 to omega-3 ratio may help decrease
disease risk [112].
Collectively, inulin and ITFs have demonstrated a large array of benefits in
the literature; however, more research needs be conducted in order to
understand the aforementioned inconsistencies. Further, very little research
exists regarding inulin and the brain, an exciting area of future discoveries.

1.6

Scope of Dissertation
The overall objective of our project is to use the prebiotic inulin to

modulate the gut microbiota, reducing the risk of developing Alzheimer’s disease
(AD)-like symptoms. For all aims, we will use a mouse model of C57BL/6
background that overexpresses human Aβ via 5 familial-AD (5xFAD) mutations
and expresses either the knocked-in human APOE3 (E3FAD) or APOE4
(E4FAD) gene. Notably, a prevention strategy can be utilized in these mice as
this mouse model gives us a known timeline of when to treat the mice with the
prebiotic inulin. Our central hypothesis is that the prebiotic inulin will restore
metabolic function and reduce AD pathology, including Aβ and
neuroinflammation, in asymptomatic E4FAD mice. Our rationale is that once we
learn if manipulation of the gut microbiota with the prebiotic inulin can alter the

28

gut-brain axis and decrease AD risk factors, we can administer innovative
treatments for its prevention. As such, we will test our central hypothesis by
these three specific aims:
Specific Aim 1. To identify the effects of the prebiotic inulin on the
gut microbiota and induced metabolism changes thereof between E3FAD
and E4FAD mice. This chapter will discuss the differences in the gut microbiota
between E3FAD and E4FAD mice along with the effect of the prebiotic inulin on
thereof compared to the control diet. Further, it will test for potential metabolites,
such as the short chain fatty acids (SCFAs), generated by the gut microbiota with
and without prebiotic treatment in the cecum and in fecal culture.
Specific Aim 2. To identify the effects of the prebiotic inulin on
metabolism in the periphery and central nervous system (CNS) between
E3FAD and E4FAD mice. This chapter will discuss the effect of the prebiotic
inulin on metabolism in blood plasma, in vivo brain, and brain tissue between
E3FAD and E4FAD mice. Specifically, metabolites produced from the prebiotic
inulin in the gut microbiota that may have an impact on the brain will be
assessed.
Specific Aim 3. To identify the effects of the prebiotic inulin on AD
risk factors and pathology between E3FAD and E4FAD mice. This chapter
will discuss if the impact of the prebiotic inulin can reach the brain and decrease
AD risk factors, including CBF, inflammation, anxiety, and cognition, and Aβ
aggregation in E3FAD and E4FAD mice and any differences seen between
E3FAD and E4FAD mice.
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Chapter 2
2.1

Methods and Materials

Animals, Caging, and Diet Information
For all aims, the EFAD transgenic mouse model (E3FAD and E4FAD) was

used. This C57BL/6 background mouse model is a cross between transgenic
mice that overexpress Aβ via 5 familial-AD (5xFAD) mutations with transgenic
mice that have either the target replacement human APOE3 or APOE4 allele. We
determined the sample size (N = 15/group, Male:Female = 50/50) via power
analysis to ensure comparison at a 0.05 level of significance and a 90% chance
of detecting a true difference of each measured variable between groups. Each
mouse was given its own cage housed in a specific pathogen-free facility in order
to avoid the potential for hostility when combining unfamiliar mice into one cage.
Further, mice were house independently for gut microbiome analysis due to the
potential for microbiome transfer, e.g. mice eating each other’s feces giving them
a very similar gut microbiome. Thus, the mice would be N = 1 for that particular
cage. Individual housing will also help us avoid cage effects [113]. E3FAD and
E4FAD mice were weighed biweekly, given ad libitum access to food and water,
and fed either a prebiotic or vehicle control diet (detailed in Table 3.1) starting at
3 months of age. Both the prebiotic and vehicle control diet are modifications of
TestDiet’s AIN-93G Semi-Purified Diet 57W5. Experimental procedures,
including magnetic resonance imaging and animal behavior tests, started when
mice reached 7 months of age and after completion of these experiments, the
mice were sacrificed with cecum weight measured and brain, blood, cecal
contents, and intestinal tissue collected. All experimental procedures were
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performed according to NIH guidelines and approved by the Institutional Animal
Care and Use Committee (IACUC) at the University of Kentucky (UK).

2.2

Fecal Bacterial Culture
Fecal samples were collected from 7-month old E3FAD and E4FAD mice

fed a standard chow diet and pooled together into their respective groups with
175 mg per sample weighed. The samples were placed in an anaerobic chamber
and transferred to a clean tube containing 1.5 ml media. The samples were
mashed into a semi-suspension, sealed, and taken out of the chamber. Samples
are centrifuged at 500 rpm for 5 minutes. A 10-cc syringe is used to pull 8 mLs of
the supernatant into an anaerobic tube. Samples are centrifuged again at 3000
rpm for 10 minutes. Next, the samples are aspirated and maintained in anaerobic
conditions. The pellets are suspended in 9 mL media and separated into tubes.
Next, either inulin (5g/L) or the control, glucose (5g/L) were added. The samples
sit for either 24 or 48 hours with subsequent collection of 1 mL from each
sample. The samples are centrifuged at 21,000 g for 2 minutes and supernatant
collected. The samples can then be frozen until further analysis. All groups were
run in triplicate.

2.3

Gut Microbiome Analysis
For fecal DNA amplification, fecal samples were collected from all mice

per group (N = 15/group, M:F = 50/50). A DNeasy PowerSoil Kit (Qiagen, Hilden,
Germany, Cat. No. 12888-100) was used for fecal DNA extraction, according to
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the manufacturer’s protocol. Genomic DNA was PCR amplified with primers
CS1_515F and CS2_926R [114] targeting the V4-V5 regions of microbial 16S
rRNA genes using a two-stage “targeted amplicon sequencing (TAS)” protocol
[115, 116]. First stage amplifications were performed with the following
thermocycling conditions: 95˚C for 3 minutes, 28 cycles of 95˚C for 45 seconds,
55˚C for 45 seconds, 72˚C for 90 seconds and final elongation at 72˚C for 10
minutes. Barcoding was performed using a second-stage PCR amplification with
Access Array Barcode Library for Illumina Sequencers (Fluidigm, South San
Francisco, CA; Item# 100-4876). The pooled libraries, with a 15% phiX spike-in,
were loaded on a MiSeq v3 flow cell, and sequenced using an Illumina MiSeq
sequencer, with paired-end 300 base reads. Fluidigm sequencing primers,
targeting the CS1 and CS2 linker regions, were used to initiate sequencing. Demultiplexing of reads was performed on instrument. Second stage PCR
amplification and library pooling were performed at the DNA Services (DNAS)
facility within the Research Resources Center (RRC) at the University of Illinois
at Chicago (UIC). Sequencing was performed at the W.M. Keck Center for
Comparative and Functional Genomics at the University of Illinois at UrbanaChampaign (UIUC).
For microbial analysis, forward and reverse reads were merged using
PEAR [117]. Primer sequences were identified using Smith-Watermann
alignment and trimmed from the sequence. Reads that lacked either primer
sequence were discarded. Sequences were then trimmed based on quality
scores using a modified Mott algorithm with a PHRED quality threshold of p =
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0.01, and sequences shorter than 300 bases after trimming were discarded.
QIIME v1.8 was used to generate operational taxonomic unit (OUT) tables and
taxonomic summaries [118]. Briefly, the resulting sequence files were merged
with sample information. OTU clusters were generated in a de novo manner
using the UCLUST algorithm with a 97% similarity threshold [119]. Chimeric
sequences were identified using the USEARCH61 algorithm with the
GreenGenes 13_8 reference sequences [120]. Taxonomic annotations for each
OTU were using the UCLUST algorithm and GreenGenes 13_8 reference with a
minimum similarity threshold of 90% [119, 120]. Taxonomic and OTU abundance
data were merged into a single OTU table and summaries of absolute
abundances of taxa were generated for all phyla, classes, orders, families,
genera, and species present in the dataset. The taxonomic summary tables were
then rarefied to a depth of 10,000 counts per sample.
Shannon and Bray-Curtis dissimilarity indices were calculated with default
parameters in R using the vegan library [121, 122] and visualized as box plot and
NMDS plot, respectively. Shannon index is used to calculate -diversity, or the
species richness within a single habitat, via 𝐻 = ∑𝑠𝑖=𝑙(𝑝𝑖 ∗ 𝑙𝑛 𝑝𝑖 ) where H =
Shannon diversity index, pi = fraction of the entire population made up of species
i, S = number of species, ln = natural logarithm, and  = sum of species. A higher
H value indicates a more diverse community within a particular sample. BrayCurtis dissimilarity is used to calculate -diversity, the diversity of taxonomic
abundance between difference samples, via 𝐵𝐶𝑖𝑗 = 1 −

2𝐶𝑖𝑗
𝑆𝑖 +𝑆𝑗

where i and j = the

two sites, Si = total number of specimens on site i, Sj = total number of
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specimens counted on site j, and Cij = sum of only lesser counts for each species
in both sites. The rarefied genus data, taxonomic level 6, were used to calculate
both indices. Plots were generated in R using the ggplot2 library [123].
Significant differences among tested groups was determined using the KruskalWallis one-way analysis of variance and analysis of variance using distance
matrices (ADONIS). The group significance tests were performed on the rarefied
genus data, taxonomic level 6 (genus), using the group_significance.py script
within the QIIME v1.8 package.

2.4

Plasma Scyllo-Inositol
A subset of 10 mice per group (N = 10, M:F = 50/50) was used for testing

with a total of 50 ul mouse plasma mixed with 200 ul acetone, for a final
concentration of 80%, to precipitate protein at -80C for 30 minutes. The
precipitation was centrifuged out at 21000 g for 20 minutes at 4C. The
supernatants were lyophilized overnight and reconstituted in D2O (> 99.9%,
Cambridge

Isotope

Laboratories,

MA)

containing

0.1

mM

EDTA

(Ethylenediaminetetraacetic acid, Sigma Aldrich, St. Louis, MO) and 0.5 mM d62,2-dimethyl-2-silapentane-5-sulfonate (DSS) (Cambridge Isotope Laboratories,
Tewksbury, MA) as NMR internal standard. All NMR experiments including 1D 1H
and 2D

1H

HSQC were performed on an Agilent DD2 14.1 Tesla NMR

spectrometer (Agilent Technologies, CA) equipped with a 3 mm inverse triple
resonance HCN cryoprobe. All spectra were processed using MNova software
(MestreLab, Spain). 1D 1H spectra were acquired with standard PRESAT pulse
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sequence at 15 C with soft pulse pre-saturation on the HOD resonance
frequency to suppress water signal. A total of 16,384 data points was acquired
with 2 seconds acquisition time, 512 transients, 12 ppm spectral width, and 4
seconds recycle delay time during which water peak was irradiated by soft pulse
for suppression. The spectra were then linear predicted and zero filled to 128 k
points and apodized with a 1 Hz exponential line broadening function. For
quantification, the peak intensities were extracted using the peak-fitting
deconvolution method provided by MNova software. The peak intensity of scylloinositol resonant at 3.34 ppm were converted into nmoles by calibration against
the peak intensity of internal standard DSS (with known quantify of 27.5 nmoles)
at 0 ppm. 2D heteronuclear single quantum coherence (HSQC) were acquired to
help confirm the peak assignments. The 2D HSQC spectra were recorded with
13C

adiabatic decoupling scheme for broad range decoupling during proton

acquisition time of 0.25 seconds. 1,796 data points were collected each transient
and a total of 16 transients were acquired with 12 ppm spectral width. A total of
256 increments were collected in the carbon F1 dimension with a spectral width
of 200 ppm. The HSQC spectra were linear predicted once and zero filled to 4 k
data points in the F2 proton dimension and 1 k points in the F1 carbon
dimension. The scyllo-inositol peak resonance was at 3.34 ppm in proton
dimension and 70.3 ppm in carbon dimension.
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2.5

Metabolomics Profiling
For all aims, mouse blood, brain, and cecal contents were collected. The

whole blood and brains were then sent to Metabolon (Durham, NC) for
metabolomic profile (N = 8/group, M:F = 50/50). The cecal contents and whole
blood were sent for SCFA analysis. For the metabolomic profiling, metabolon’s
standard solvent extraction method was used to prepare the samples, which
were then equally split for analysis via liquid chromatography/mass spectrometry
(LC/MS) or gas chromatography/mass spectrometry (GC/MS) using their
standard protocol [124].
For SCFA analysis in the whole blood (N = 8/group in ng/mL) and cecal
contents (N = 8/group in g/g), 8 SCFAs were analyzed by LC-MS/MS. These
were as follows: acetic acid (C2), propionic acid (C3), isobutyric acid (C4), 2methylbutyric acid (C5), isovaleric acid (C5), valeric acid (C5), and caproic acid
(C6). Both sets of samples are stable labelled with internal standards and
homogenized in an organic solvent. The samples are then centrifuged followed
by an aliquot of the supernatant used to derivatize to form SCFA hydrazides.
This reaction mixture is subsequently diluted, and an aliquot is injected into an
Agilent 1290/AB Sciex QTrap 5500 LCMS/MS system. This system is equipped
with a C18 reversed phase UHPLC column operated in negative mode using
electrospray ionization (ESI). The raw data was analyzed by AB SCIEX software
(Analyst 1.6.2) with reduction of the data done in Microsoft Excel 2013. Analysis
was done in a 96-well plate with two calibration curves and 6-8 quality control
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samples per bath. Samples were labeled BLOQ if they fell below the quantitation
limit and ALOQ if they fell above the quantitation limit.
For sample preparation of the rest of the samples, each sample was
accessioned into a LIMS system, assigned a unique identifier, and stored at -70
ºC. To remove protein, dissociate small molecules bound to protein or trapped in
the precipitated protein matrix, and to recover chemically diverse metabolites,
proteins were precipitated with methanol, with vigorous shaking for 2 minutes
(Glen Mills Genogrinder 2000) as described previously [124, 125]. The resulting
extract was divided into four fractions: one for analysis by ultra-high-performance
liquid chromatography-tandem mass spectrometry run in positive mode (UPLCMS/MS+), one for analysis by UPLC-MS/MS run in negative mode (UPLCMS/MS-), one for analysis by gas chromatography–mass spectrometry (GC-MS),
and one aliquot was retained for backup analysis, if needed.
For mass spectrometry analysis, non-targeted UPLC-MS/MS and GC-MS
analyses were performed at Metabolon, Inc. as described [124-126].

The

UPLC/MS/MS portion of the platform incorporates a Waters Acquity UPLC
system and a Thermo-Finnegan LTQ mass spectrometer, including an
electrospray

ionization

(ESI)

source

and

linear

ion-trap

(LIT)

mass

analyzer. Aliquots of the vacuum-dried sample were reconstituted, one each in
acidic or basic LC-compatible solvents containing 8 or more injection standards
at fixed concentrations (to both ensure injection and chromatographic
consistency). Extracts were loaded onto columns (Waters UPLC BEH C18-2.1 x
100 mm, 1.7 μm) and gradient-eluted with water and 95% methanol containing
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0.1% formic acid (acidic extracts) or 6.5 mM ammonium bicarbonate (basic
extracts). The instrument was set to scan 99–1000 m/z and alternated between
MS and MS/MS scans.
Samples destined for analysis by GC-MS were dried under vacuum
desiccation for a minimum of 18 h prior to being derivatized using
bis(trimethylsilyl)trifluoroacetamide (BSTFA) as described [127]. Derivatized
samples were separated on a 5% phenyldimethyl silicone column with helium as
carrier gas and a temperature ramp from 60° to 340°C within a 17-minute period.
All samples were analyzed on a Thermo-Finnigan Trace DSQ fast-scanning
single-quadrupole MS operated at unit mass resolving power with electron
impact ionization and a 50–750 atomic mass unit scan range. The instrument is
tuned and calibrated for mass resolution and mass accuracy daily.
For quality control, all columns and reagents were purchased in bulk from
a single lot to complete all related experiments. For monitoring of data quality
and process variation, multiple replicates of extracts from a pool of human
plasma were prepared in parallel and injected throughout the run, interspersed
among the experimental samples. Instrument variability was determined by
calculating the median relative standard deviation (RSD) for the standards that
were added to each sample prior to injection into the mass spectrometers
(median RSD = 4%; n = 21 standards). Overall process variability was
determined by calculating the median RSD for all endogenous metabolites (i.e.,
non-instrument standards) present in 100% of technical replicate samples
created from a homogeneous pool containing a small amount of all study
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samples (median RSD = 6%; n = 170 metabolites). In addition, process blanks
and other quality control samples are spaced evenly among the injections for
each day, and all experimental samples are randomly distributed throughout
each day’s run.
For compound identification, quantification, and data curation, metabolites
were identified by automated comparison of the ion features in the experimental
samples to a reference library of chemical standard entries that included
retention time, molecular weight (m/z), preferred adducts, and in-source
fragments as well as associated MS spectra and curated by visual inspection for
quality control using software developed at Metabolon [128]. Identification of
known chemical entities was based on comparison to metabolomic library entries
of more than 2,800 commercially-available purified standards. Subsequent
quality control (QC) and curation processes were utilized to ensure accurate,
consistent identification and to minimize system artifacts, mis-assignments, and
background noise. Library matches for each compound were verified for each
sample. Peaks were quantified using area under the curve. Raw area counts for
each metabolite in each sample were normalized to correct for variation resulting
from instrument inter-day tuning differences by the median value for each runday, therefore setting the medians to 1.0 for each run. This preserved variation
between samples but allowed metabolites of widely different raw peak areas to
be compared on a similar graphical scale. Missing values were imputed with the
observed minimum after normalization. For bioinformatics, the LIMS system
encompasses sample accessioning, preparation, instrument analysis and
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reporting, and advanced data analysis. Additional informatics components
include data extraction into a relational database and peak-identification
software; proprietary data processing tools for QC and compound identification;
and a collection of interpretation and visualization tools for use by data analysts.
The hardware and software systems are built on a web-service platform utilizing
Microsoft’s .NET technologies which run on high-performance application servers
and fiber-channel storage arrays in clusters to provide active failover and loadbalancing.
For metabolite quantification and data normalization, peaks were
quantified using area-under-the-curve and a data normalization step for multiple
day studies was utilized to correct any variance in instrument inter-day tuning
differences. For one day studies, no normalization is necessary except for when
accounting for an additional factor to account for any differences in metabolite
levels due to differences in amount present in each sample.
For statistical analysis, two types of statistical analyses were performed;
significance tests and classification analysis. Statistical analysis is performed in
ArrayStudio on log transformed data. For analyses not standard to ArrayStudio,
either R or JMP are used. Multiple significance tests and classification methods
are used. These include Welch’s two-sample t-test, Matched Pairs t-test, oneway ANOVA, two-way ANOVA, and two-way repeated measures ANOVA. Also,
correlation, and Hotelling’s T2 test were used. For statistical significance testing,
p-values and q-values using False Discovery Rate (FDR) were utilized. Finally,
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Random Forest, hierarchical clustering, and Principal Components Analysis
(PCA) were used.

2.6

Magnetic Resonance Imaging (MRI)
All MRI experiments were performed on a 7T MR scanner (Clinscan,

Bruker BioSpin, Germany) at the Magnetic Resonance Imaging & Spectroscopy
Center at the UK. A subset of mice were randomly chosen from each group to
undergo testing (N = 8-10/group). Mice were anesthetized with 4.0% isoflurane
for induction and then maintained in a 1.2% isoflurane and air mixture using a
nose cone. Respiration rate (50-80 breaths/minute) and rectal temperature (37 ±
1 °C) were continuously monitored and maintained. T2-weighted structural
images were acquired with field of view (FOV) =18 x18 mm2, matrix = 256 x 256;
slice thickness = 1 mm, 10 slices, repetition time (TR) = 1500 ms, and echo time
(TE) = 35 ms. Quantitative CBF (with units of mL/g per minute) was measured
using MRI-based pseudo-continuous arterial spin labeling (pCASL) techniques
[129]. A whole-body volume coil was used for transmission and a mouse brain
surface coil was placed on top of the head for receiving. Paired control and label
images were acquired in an interleaved fashion with a train of Hanning windowshaped radiofrequency pulses of duration/spacing = 200/200 μs, flip angle = 25°
and slice-selective gradient = 9 mT/m, and a labeling duration = 2100 ms [130].
The images were acquired by 2D multi-slice spin-echo echo planner imaging with
FOV =18 x18 mm2, matrix =128 x 128, slice thickness = 1 mm, 10 slices, TR =
4,000 ms, TE = 35 ms, and 120 repetitions. pCASL image analysis was
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employed with in-house written codes in MATLAB (MathWorks, Natick, MA) to
obtain quantitative CBF [131].
The next MRI technique used is magnetic resonance spectroscopy (MRS),
or the measurement of metabolites in vivo [132]. MRS was being conducted in
mouse brains, specifically in the hippocampus, with the following metabolites
measured: alanine (Ala), total choline (TCho), glutamate-glutamine complex
(Glx), myo-inositol (mI), lactate (Lac), NAA, phosphocreatine (PCr), total creatine
(TCr), and taurine (Tau). These metabolites are plotted on a graph of signal
intensity versus frequency. The following were used for a water-suppressed
spectrum to test for these metabolites: TR = 1500 ms, TE = 135 ms, spectral
width = 60 Hz, and average = 400. A voxel (2.0 mm x 5.0 mm x 1.3 mm) is
placed over the bilateral hippocampus. Next, a non-water suppressed spectra is
performed with 10 averages. Both of these spectra will be processed using the
LCModel software to find the absolute concentration of the metabolites. To
quantify the concentrations of the metabolites, the following equation was
utilized: [m] = (Sm/Swater)[water]CnCav where [m] is the metabolite concentration,
Sm is the metabolite intensity acquired from MRS, Swater is the water intensity
acquired from MRS, [water] is the concentration of water (55.14mM at 310K), C n
is the correction for the number of equivalent nuclei for each resonance, and C av
is the correction for the number of averages [133].
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2.7

Amyloid-β Staining
Mouse brains were collected (N = 5/group, M:F = 50/50) upon sacrifice and

immediately put into 10% neutral buffered formalin for 24-48 hours. After this
time period, the brains were transferred into 90% ethanol. Next, the brains were
sent to the COCVD Pathology Research Core at the University of Kentucky to be
embedded and sectioned onto microscope slides for immunohistochemistry. The
sectioned tissue undergoes rehydration followed by tissue pretreatment in 90%
formic acid for 3 minutes. The tissue was then treated with 3% H2O2 and 10%
methanol for 30 minutes. Next, a M.O.M. Kit (Vector Laboratories, Inc.
Burlingame, CA) was used following the standard protocol. A was identified
using an anti-A1-17 mouse monoclonal 6E10 antibody (1:3000; Signet
Laboratories, Dedham, MA). Following this portion of the protocol, a DAB
substrate kit (also Vector Laboratories, Burlingame, CA) was used for
visualization. Next, a background stain utilizing NISSL was completed followed
by dehydration. The slides were next imaged on the Aperio ScanScope XT
Digital Slide Scanner System in the University of Kentucky Alzheimer’s Disease
Center Neuropathology Core Laboratory (20x magnificantion) and uploaded to
the online database. Aperio ImageScope (version 12.3.2.8013) was used to
analyze total anti-A counted at 20x magnification (0.495px/um). 10 boxes (ROIs
that are 600x600x600 microns) were randomly placed in each sample image and
counted for percent positive A (number of positive + number of strong
positive/total number).
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2.8

NanoString Array
For RNA isolation and quantification, dissected hippocampus was

processed for RNA isolation following manufacturer’s protocol (N = 5/group, all
male) (Qiagen RNeasy Plus #74136). Quality and concentration of eluted RNA
was measured by Nanodrop. 200ng of total RNA per sample was quantified
using a NanoString array that consisted of 561 gene targets (Mouse Immunology
v2 CodeSet). Following quality and housekeeping control normalization, there
were a total of 318 genes that were above the background threshold.

2.9

Animal Behavior Tests
All behavior tests were conducted over a two-week period with each test

starting at the same time each morning (N = 7-9/group, M:F = 50/50). For each
mouse, Elevated Plus Maze (EPM) was done first immediately followed by the
Open Field Test and the Novel Object Recognition (NOR) test the next day.
Radial Arm Water Maze (RAWM) testing was then carried out starting the day
after NOR. All tests were carried out in the Rodent Behavior Center at the
University of Kentucky.
For elevated plus maze, all mice underwent three behavior tests. The first
test is the EPM. We used the EPM to evaluate anxiety of the mice [129, 134].
The EPM consists of two open and two closed arms elevated 100 cm above the
floor. Closed arms are perceived as safe zones, and thus mice with higher
anxiety had tendency to stay in the closed arms. We determined the anxietyrelated behavior by measuring the time spent in the closed arms over the 1-
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minute test session by EthoVision XT 8.0 video tracking software (Noldus
Information Technology).
For the open field test (OF), activity was recorded with EthoVision XT 8.0
video tracking software (Noldus Information Technology). Each chamber was
divided into a central and peripheral zone with the peripheral zone being next to
the walls of the chamber. Data was collected for 15 minutes with edge duration
being the amount of time the mice spent in the peripheral zone. This test is
designed to assess anxiety-like behavior in the mice in response to a new, novel
environment [135].
For novel object recognition (NOR), the second behavioral test, used to
test spatial recognition memory [136]. This task of recognition memory utilizes
the fact that animals will spend more time exploring a novel object compared to
an object that they are familiar with in order to satisfy their innate
curiosity/exploratory instinct. Mice were given 10 minutes to explore two of the
same objects in the “A/A” session. For the 10-minute “A/B” test session, one of
the A objects was replaced by a novel object (B). There was a 2-hour delay
between the A/A and A/B sessions. The total time mice spend investigating the
objects was recorded and scored by the fully automated EthoVision XT 8.0 video
tracking software (Noldus Information Technology). The D2 discrimination index
was calculated by: D2 = (TB-TA) ÷ (TB +TA), where TB is the time spent with the
novel object B, and TA is the time spent with the familiar object A.
The final test is radial arm water maze (RAWM), used to measure both
spatial working memory and spatial reference memory [129, 137, 138]. The
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RAWM task was conducted as described previously [133], following a 2-day
testing paradigm. A staggered training schedule was used, running the mice in
cohorts of ten mice, while alternating the different cohorts through the trials over
day 1 and day 2 of the test. This alternating protocol was used to avoid the
learning limitations imposed by massed sequential trials and to avoid fatigue that
may result from consecutive trials. Day 1 is the “learning” phase where mice went
through three blocks (Blocks 1-3; 5 trials in each block) to test learning and shortterm spatial memory. Day 2 is the “recall” phase where mice went through three
additional blocks (Blocks 4-6) to test long-term memory after a 24-hour retention
period to locate the platform. It is expected that after the two-day training, the
mouse with intact memory can find the platform with minimal errors. Geometric
extra-maze visual cues were fixed throughout the study on three sides of the
curtains. Visual platform trials were included in the training and were used to
determine if visual impairment could be a cofounding variable. Mouse
performance was recorded by EthoVision XT 8.0 video tracking software (Noldus
Information Technology) data analyzed by the EthoVision software for the
number of incorrect arm entries, which are defined as errors. The video was
reviewed for each mouse to ensure that the mice did not employ non-spatial
strategies, such as chaining, to solve the task.

2.10 Statistical Analysis
All statistical analyses were completed using GraphPad Prism (GraphPad,
San Diego, CA, USA). For all chapters, two-sample t-test and 2-way ANOVA was
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performed for determination of differences between groups along with Tukey’s
multiple comparisons test. For Metabolon, log transformations were conducted
followed by ANOVA for identification of biochemicals that were significantly
different between groups. Between group differences were assessed using pvalue and q-value, or false discovery rate. For the NanoString Array analysis,
data are plotted as the mean ratio expression with their respective adjusted pvalue (Benjamini-Hochberg corrected). Further, 2-way ANOVA was used along
with Sidak posthoc multiple comparisons correction for the individual genes.
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Chapter 3

Specific Aim 1: To identify the effects of the prebiotic inulin on

the gut microbiota and induced metabolism changes thereof between
E3FAD and E4FAD mice.
3.1

Summary
The gut microbiota plays a profound role on the host and recently, this has

been found true in the brain and in neurological diseases such as AD. The
differences between the gut microbiota and effects of consuming the prebiotic
inulin on APOE3 and APOE4 carriers is unknown. PURPOSE: The purpose of
this aim to identify the effects of the prebiotic inulin on the gut microbiota and
induced metabolism changes thereof between E3FAD and E4FAD mice.
RESULTS: Firstly, mice bodyweight and food intake were not changed due to the
prebiotic diet, however, E3FAD and E4FAD mice fed the prebiotic inulin had a
significantly larger cecum than control fed mice. In the cecal contents, both
E3FAD and E4FAD fed the prebiotic inulin had significantly increased SCFAs but
decreased isobutyrate. Next, our fecal culture experiment found an increase in
scyllo-inositol in the inulin cultures compared to controls. In both the cecal
contents and fecal culture, the E3FAD mice had a larger production of the
aforementioned metabolites compared to the E4FAD mice. Further, the prebiotic
inulin fed E3FAD mice altered the gut microbiota via decreased -diversity,
significantly different -diversity, and increased beneficial and SCFA producing
taxa, and decreased deleterious bacterial taxa. The E4FAD mice fed the
prebiotic inulin saw more modest differences compared to the control fed mice
with the gut microbiota showcasing a significantly different -diversity, but not 48

diversity, and also increased levels of beneficial taxa at the genus level.
However, there were no differences due to the FAD mutations. CONCLUSIONS:
To conclude, the prebiotic inulin beneficially impacted the host through increased
production of beneficial metabolites such as the SCFAs and scyllo-inositol along
with increasing beneficial taxa and decreasing deleterious taxa However, the
E3FAD mice and E4FAD mice fed the prebiotic inulin showcased variation in the
aforementioned outcomes as E3FAD mice appeared to gain more benefit due to
the prebiotic inulin than did the E4FAD mice. Due to this, we believe prebiotics
can be a beneficial and translatable nutritional intervention to improve gut health
but taking genetics into account is highly warranted.

3.2

Introduction
The gut microbiota, or the trillions of bacteria in our gut, play a profound

role on our health [42]. Indeed, the gut microbiota has been demonstrated to
beneficially impact the host a variety of ways including through the immune
system [139]. Recently, the bi-directional communication between the gut and
the brain, or gut-brain axis (GBA), has become a topic of intense investigation
[140]. Indeed, it appears the gut microbiota plays a role in anxiety and
depression [141], and in other neurological disorders such as AD [142]. Recent
work has found that AD patients have a distinct gut microbiota compared to
controls [143] with alterations also seen in an AD mouse model [144]. Further,
Harach et al. found that in an AD mouse model, the germ-free mice had less
amyloid pathology than those that actually had a gut microbiota [41]. It is worth
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noting that studies by Oria et al. have found human APOE4 carriers to have
protection from diarrhea in early childhood, providing a survival advantage [39].
Further, in favela children in Northeast Brazil, this group found that APOE4 was
protective against cognitive deficits due to enteric infections and diarrhea [145].
Due to this, we believe that our E3FAD and E4FAD mice will show a vastly
different response to the prebiotic inulin and metabolites produced but in both,
beneficial modulation of the gut microbiota by the prebiotic inulin could help
prevent AD-like symptoms.
Using prebiotics such as inulin may be used as a preventative measure in
combating AD. Indeed, prebiotics are, as stated by one source, “a selectively
fermented ingredient that allows specific changes, both in the composition and/or
activity in the gastrointestinal microflora that confers benefits upon host wellbeing and health [146].” Prebiotics must resist upper gastrointestinal (GI)
enzymes, be fermented in the lower GI, and selectively stimulate the growth of
beneficial bacteria [147]. Further, during the fermentation of prebiotics, beneficial
metabolites are produced such as the short chain fatty acids (SCFAs) butyrate,
acetate, and propionate, demonstrated to beneficially impact the brain [148, 149].
The prebiotic chosen for this project is inulin, derived from chicory root, but also
found in other vegetables, fruits, and grains. Inulin is quite possibly the most well
studied prebiotic and is well known for its numerous beneficial properties
including increased mineral absorption, decreased inflammatory bowel syndrome
(IBS) scores, and reduced cholesterol [101, 103]. Further, the prebiotic inulin has
been demonstrated to increase the size of the cecum, which is thought to
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indicate increased fermentation of beneficial metabolites and microbial content
[150, 151]. We believe that using the prebiotic inulin to beneficially modulate the
gut microbiota in E3FAD and E4FAD mice will lead to a change in metabolism
via an increase in the fermentation of beneficial metabolites that could potentially
help prevent AD pathology.
The objective of this aim was to identify the effect of the prebiotic inulin
and changes in the metabolism thereof between E3FAD and E4FAD mice. We
hypothesized that the prebiotic inulin will beneficially modulate the gut microbiota
and increase metabolite production in E3FAD and E4FAD mice. Specifically, we
examined the body weight, food intake, and cecum weight of the mice along with
an examination of the gut microbiota and its taxonomy in 16S rRNA sequencing
and metabolites produced in the cecal contents and in fecal bacterial culture.

3.3

Results

3.3.1 Body Weight and Food Intake
Table 3.1 demonstrates the diet composition of the prebiotic and vehicle
control diets with the prebiotic diet containing 8% fiber from inulin and the vehicle
control diet containing 8% fiber from cellulose. E3FAD and E4FAD were fed
either the prebiotic or control diet for 4-months beginning at 3-months of age. To
ensure the prebiotic diet did not alter bodyweight and food intake in the mice,
bodyweight and food intake were measured biweekly and compared between
groups. E3FAD and E4FAD mice that were fed the prebiotic diet saw no
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significant differences in body weight (Fig. 3.1a) or food intake (Fig. 3.1b)
compared to control fed mice.

3.3.2 Cecum Weight and Cecal Metabolites
The cecum, with cecal contents intact, was weighed upon sacrifice when
the mice were around 7-months of age. The cecal contents of the mice were then
collected and sent to Metabolon (Durham, NC) for metabolomics profiling via LCMS/MS. Due to the increased fermentation potential of the prebiotic inulin, we
expected a change in cecum size between prebiotic and control fed mice.
Indeed, mice that were fed the prebiotic inulin saw a drastically significant
increase in cecum size compared to control fed mice in both E3FAD and E4FAD
mice with an even greater increase seen in the E3FAD mice. Thus, we believed
cecal metabolite production may vary between groups with mice fed the prebiotic
inulin seeing more production. Indeed, both E3FAD and E4FAD mice fed the
prebiotic inulin saw a significant increase in butyrate (Fig. 3.3b), acetate (Fig.
3.3c), and propionate (Fig. 3.3d) but a decrease in isobutyrate (Fig. 3.3e).
Further, the E3FAD mice saw a significantly greater increase in cecal propionate
compared to the E4FAD mice fed the prebiotic inulin. The full results of short
chain fatty acids is in Table 3.2. Overall, these results indicate that the prebiotic
inulin causes an increase in fermentation in the cecum leading to a larger cecum
and more beneficial metabolite production with an even greater increase seen in
E3FAD mice, perhaps due to bacterial composition of E3FAD mice better able to
produce SCFAs.
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3.3.3 Scyllo-Inositol in Fecal Bacterial Culture
To confirm that scyllo-inositol is indeed formed from gut microbiota
bacteria, fecal samples from 7-month old E3FAD and E4FAD mice on a standard
chow diet were collected and pooled into their respective groups and fecal cell
suspensions were made under anaerobic conditions. The samples were given
either inulin or a control, glucose, for 24 or 48 hours at which point the
supernatant was collected and measured for scyllo-inositol via NMR. When inulin
was added, scyllo-inositol formation was increased compared to the cultures that
were only given glucose in both E3FAD and E4FAD mice, albeit only significantly
in the E3FAD mice (Fig. 3.2a). However, the E3FAD fecal culture saw a much
greater increase in scyllo-inositol compared to the E4FAD fecal culture (Fig.
3.2a). These results indicate that the prebiotic inulin does indeed increase scylloinositol formation in the gut microbiota in both E3FAD and E4FAD mice. Whether
this change is due to inulin increasing proliferation of scyllo-inositol creating
bacterial taxa or for other reasons remains to be determined. Further, E3FAD
and E4FAD appear to have a different gut microbiota that impacts levels of
scyllo-inositol production, a consideration that needs to be given to future studies
and for carriers of these specific alleles.

3.3.4 Gut Microbiota Diversity and Taxonomy
To determine the differences in the gut microbiota between groups fed the
prebiotic and control diet along with differences in E3FAD and E4FAD mice, fecal
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samples were collected from each mouse upon reaching 7-months of age
followed by DNA extraction and amplification. The DNA was then utilized for 16S
rRNA sequencing and subsequent diversity and taxonomy analysis. For gut
microbiota analysis in E3FAD mice, -diversity, a measure of the diversity within
a sample by measuring the richness and evenness of that sample, was
measured via the Shannon Diversity Index, H value, for fecal microbial
communities at the genus taxonomic level. A higher H value indicates a more
diverse community within that particular sample. A significant decrease was seen
in E3FAD mice fed the prebiotic inulin compared to the control group (Gausian
link function results, p < 0.0001) (Fig. 3.4a). Next, -diversity, a measure of the
diversity of taxonomic abundance between different samples, was measured via
the Bray-Curtis dissimilarity index at the genus taxonomic level. E3FAD mice fed
the prebiotic inulin saw a significant difference in -diversity compared to the
controls (Fig. 3.4b) (ANOSIM R statistic = 0.877, p-value = 0.001). For E4FAD
mice, no difference was seen in -diversity (Gausian link function results, p =
0.418) (Fig. 3.4c) but a significant difference was observed in -diversity
(ANOSIM R statistic = 0.454, p-value = 0.001) (Fig. 3.4d). Significant changes in
taxa were observed in numerous bacterial taxa due to the prebiotic inulin. In
E3FAD mice fed the prebiotic inulin compared to the controls, a significant
increase was seen in notable taxa at the genus level such as Bifidobacterium,
Lactobacillus, Escheridia, Allobaculum, and Prevotella (Table 3.2). Moderate
increases were seen in Akkermansia and Mucispirillum. In contrast, Bacteroides,
Turicbacter, rc4-4, Oscillospira, and Dehalobacterium were decreased. At the
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phylum level, Tenericutes were decreased in E3FAD mice fed the prebiotic inulin
while Actinobacteria was increased. In E4FAD mice fed the prebiotic inulin at the
genus level, notable taxa were increased such as Prevotella, Lactobacillus, and
Mucispirillum. In contrast, Akkermansia, Escheridia, Parabacteroides, Turibacter,
SMB53, AF12, and Dehalobacterium were decreased. No significant changes
were present at the phylum level. There were also no notably significant
differences due to the FAD mutations (Genotype). These results indicate that the
prebiotic inulin alters the gut microbiota in E3FAD and E4FAD mice in, what we
believe, a beneficial manner, despite a decrease in α-diversity in the E3FAD
mice, but by increasing beneficial taxa. However, it appears the fermentation
capabilities of E3FAD and E4FAD mice differ and this impacts the number of
beneficial metabolites produced.

3.4

Discussion
Firstly, we see that the prebiotic inulin, 8% fiber from inulin, does not

impact food intake and bodyweight in our mice compared to our control mice, 8%
fiber from cellulose. Other studies have found similar results [152]. It is notable
that inulin contains more kcal/g than cellulose, but the extra kcal/g may be
consumed by the gut bacteria during fermentation. Nonetheless, this data helps
us be rid of potential confounding factors that may be due to changes in body
weight.
Our work found that feeding the prebiotic inulin increased cecum size in
our mice, especially so in E3FAD mice. Previous studies using the prebiotic inulin
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have also found increases in cecum size [152, 153]. This is likely due to the
cecum being the primary site of inulin fermentation [150, 151]. Kuo et al. also
postulated that this may also indicate increased microbial content [152]. We
believe this increase in fermentation may lead to increased production of
beneficial metabolites, which is precisely what we saw with the SCFAs acetate,
butyrate, and propionate. Interestingly, propionate was even more significantly
increased in the E3FAD group fed the prebiotic inulin compared to the E4FAD
group fed the prebiotic inulin. However, isobutyrate was decreased in the E3FAD
and E4FAD mice fed the prebiotic inulin compared to their respective controls for
unknown reasons likely related to bacterial SCFA metabolism. Nonetheless, the
dramatic increase in SCFAs due to the prebiotic inulin does indeed confirm other
studies that inulin increases SCFA levels [112, 154]. Whether the increased
levels of SCFAs reached the periphery will be explored in the next chapter.
Next, we demonstrate with our fecal culture experiment that the prebiotic
inulin can increase scyllo-inositol production in the fecal microbiota. We can
confirm that the production of scyllo-inositol does indeed come from the gut
microbiota due to inulin feeding but we are unsure how exactly this occurs. To
our knowledge, only one particular bacterial species has been identified to
produce scyllo-inositol, Bacillus subtilis [155]. This taxon appears to produce
scyllo-inositol from myo-inositol, the more common stereoisomer of scyllo-inositol
found in foods such as fruits, beans, and nuts [156]. However, we do not
understand why the taxon would generate the metabolite from myo-inositol or
excrete the metabolite as opposed to using it as a carbon source. We also did
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not see this bacterial species in our gut microbiota data. Nevertheless, we
suspect that numerous other bacterial taxa increase scyllo-inositol production
due to the prebiotic inulin as it is stimulating the growth of certain bacterial taxa
that can produce this metabolite, increasing its production compared to the
control. Interestingly, a study in inulin fed rats found that scyllo-inositol levels
were dramatically increased in the myocardium and testes, although the reasons
why were not understood [157]. It would appear that scyllo-inositol could be
increased in numerous organs, not just the brain. Interestingly, our results
demonstrate that the fecal microbiota of the E3FAD mice given inulin were able
to produce much more scyllo-inositol at the 24- and 48-hour time points than the
E4FAD mice given either inulin or the control. In fact, the E4FAD mice given
inulin only saw an insignificant increase in scyllo-inositol at the 48-hour mark but
at still considerably lower amounts than the E3FAD mice given the inulin at either
timepoint. This indicates, similar to what we saw with the SCFAs of the cecal
contents, that E3FAD mice are able to produce more beneficial metabolites than
the E4FAD mice, probably due to better fermentation capacity. Thus, future work
on identifying which bacterial taxa produce this and other metabolites and why
the amounts may vary should be taken into consideration as these metabolites
could potentially impact the brain and other organs in a therapeutic manner.
Although research on scyllo-inositol is fairly scarce, some studies have
demonstrated that scyllo-inositol in the brain is the highest source in the body
[158] as it can pass through the blood brain barrier [159]. In fact, it increases in
the brain as we age [160], may beneficially impact GLUT4 translocation in
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muscle [161], and that it could be disturbed in certain disease states such as in
chronic alcoholism [162] and even AD [163]. Indeed, scyllo-inositol has been
demonstrated to inhibit Aβ aggregation in in vivo and in vitro trials [159, 164-167].
It is still not particularly understood how exactly the metabolite inhibits the
aggregation of Aβ, but it is thought it may cap off a plaque and inhibit further
aggregation and growth. However, it does not appear to break the plaques up
[168]. This would indicate that scyllo-inositol would work best as a preventative
measure before plaques have already or just recently formed. When comparing
scyllo-inositol to its much more common and ubiquitous stereoisomer form myoinositol, scyllo-inositol proved to be more effective at inhibiting Aβ in an AD
mouse model. In this study by McLaurin et al., they demonstrated that not only
did their transgenic AD mice have a decrease in soluble and insoluble Aβ due to
scyllo-inositol treatment, but they also had amelioration of memory deficits and a
decrease in neuroinflammation, likely a consequence of Aβ inhibition [165].
Further in this study, they found that treatment in both younger, disease-free
mice along with older mice with AD pathology, both saw significant benefits. In
humans, clinical trials using scyllo-inositol as an orally administered fast track
designation have been conducted. Unfortunately, in mild to moderate AD
patients, the high dose scyllo-inositol (1000mg and 2000mg) groups saw
increased kidney issues and thus, were discontinued. The lower dose group
(250mg) did see a significant increase in brain ventricular volume and cerebral
spinal fluid Aβ-42 but overall, the trial did not find significance in the primary
clinical outcome [169].
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In the gut microbiome, many significant differences were seen. Typically,
an increased α-diversity is thought to be beneficial [170], however, in our study
we found that the prebiotic fed mice had a decrease in α-diversity compared to
controls. Previous work by our lab and others have also found a decrease in
diversity with improvements in other outcomes [171-173]. This may indicate that
the prebiotic inulin stimulates the growth of only certain beneficial taxa,
decreasing diversity and deleterious taxa, but overall, still increasing the health of
the gut microbiota. We believe this to be the case in the E3FAD mice as the
prebiotic inulin did indeed decrease α-diversity compared to the control mice
although the E4FAD mice did not see as significant a difference. Further, both
E3FAD and E4FAD saw a significant difference in -diversity, indicative of the
powerful impact the prebiotic inulin has on the gut microbiota.
Next, we explored the differences in bacterial taxa that the prebiotic inulin
made in both E3FAD and E4FAD mice. We found that E3FAD mice fed the
prebiotic inulin demonstrated a significant increase in taxa at the genus level
such as Bifidobacterium, Lactobacillus, Escheridia, Allobaculum, and Prevotella
compared to controls. In contrast, Bacteroides, Turicibacter, rc4-4, Oscillospira,
and Dehalobacterium were decreased. Interestingly, the prebiotic inulin
increased both Bifidobacterium and Lactobacillus. Due to inulin being a prebiotic,
it is expected that Bifidobacterium and perhaps even Lactobacillus would be
increased, both of which are fairly well studied and benefit the host through
immunomodulation and emotional behavior, among other things [88, 174].
Meanwhile, Prevotella seems to proliferate on complex carbohydrates such as
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inulin and has even been associated with improved glucose metabolism in a
study using barley kernels, a dietary fiber [175]. One notable bacterial genera
that was decreased was Bacteroides, a taxa that appears to act as both
commensal and virulent, perhaps depending on the amount present [176]. At the
phylum level, Tenericutes were decreased in E3FAD mice fed the prebiotic inulin
while Actinobacteria was increased. One study has also found a decrease in
Tenericutes due to inulin although the impact of this phylum is not well
understood [177]. Further, the Actinobacteria phylum was also found to be
moderately increased in this same study but has been previously associated with
obesity [178]. Notably, this phylum does house the genus Bifidobacterium. Oddly,
the E4FAD mice found no such changes in phylum level. However, the E4FAD
mice fed the prebiotic inulin did show many differences at the genus level.
Notable taxa that were increased included Prevotella, Lactobacillus, and
Mucispirillum, all also increased in the E3FAD mice as well. In contrast,
Akkermansia, Escheridia, Parabacteroides, Turibacter, SMB53, AF12, and
Dehalobacterium were decreased in the E4FAD mice. Akkermansia is a
beneficial taxa with numerous known benefits [179], the decrease shown here
would be seen as a negative consequence especially as the E3FAD mice
actually saw a moderate increase in Akkermansia. Bifidobacterium was also not
increased in the E4FAD mice, another negative consequence. Further, SMB53
has been decreased by fermentation in one study using prebiotics [180] while
little is known about the other decreased taxa. Collectively, although there were
similarities in taxa that the prebiotic inulin was able to increase and decrease
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between E3FAD and E4FAD mice, there were also many differences, particularly
in Akkermansia and Bifidobacterium, leading us to believe that genetic factors
may indeed impact the gut microbiota and how the host responds to the
presence of a beneficial prebiotic such as inulin. However, it is also worth noting
that many of the significantly different taxa in our project have little information
associated to them, a limitation of all gut microbiota research as we have much
to learn on this topic and their impact on the host. Surprisingly, we did not see
any differences in the gut microbiota due to the FAD mutations despite literature
suggesting there may be differences [41].
Altogether, the prebiotic inulin was able to increase cecum size and the
fermentation of beneficial metabolites such as SCFAs and scyllo-inositol with the
latter produced by the fecal microbiota, demonstrating that the fecal microbiota is
indeed able to produce this metabolite. The prebiotic inulin also leads to
beneficial modulation of the gut microbiota as evidenced by the increased
number of beneficial taxa present. Interestingly, the E3FAD mice had a larger
cecum, produced more beneficial metabolites, and appeared to gain more benefit
in the gut microbiota compared to E4FAD mice. As far as we know, this is the
first time that genetic differences have been shown to impact cecum size,
metabolite production, and the response to the prebiotic inulin. Whether these
beneficial outcomes by the prebiotic inulin are able to reach and benefit the
periphery and brain will be explored in subsequent chapters.
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Table 3-1 Diet composition
Diet
Protein %
Carbohydrate %
Fat %
Fiber %
Energy (kcal/g)

Prebiotic Diet
18.2
67.8
7.1
8.0 (Inulin)
4.08
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Vehicle Control Diet
18.2
60.2
7.1
8.0 (Cellulose)
3.78

Table 3-1 Diet composition
The diet composition of the prebiotic and vehicle control diet. The prebiotic
diet contains 8% fiber from inulin while the vehicle control diet contains 8% fiber
from cellulose.
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Figure 3-1 Food intake and body weight
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Figure 3-1 Food intake and body weight.
Food intake and body weight of E3FAD and E4FAD mice fed either the
prebiotic or control diet for 4-months beginning at 3-months of age. a Inulin fed
mice had no differences in food intake. b Inulin fed mice had no differences in
body weight. Statistics were completed using 2-way ANOVA (N = 15/group, M:F
= 50/50). Error bars show mean ± SEM.
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Figure 3-2 Cecum weight and cecal metabolites
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Figure 3-2 Cecum weight and cecal metabolites
Cecum weight and cecal metabolites. The cecum, with cecal contents
intact, was weighed upon sacrifice when the mice were around 7-months of age.
The cecal contents of the mice were then collected and sent to Metabolon
(Durham, NC) for metabolomics profiling via LC-MS/MS. For more details, see
Chapter 2, section 2.5. a Both E3FAD and E4FAD mice fed inulin saw a
significant increase in cecum weight. Similarly, the cecal contents of both E3FAD
and E4FAD inulin fed mice saw a significant increase in b acetate, c propionate,
and d butyrate but a decrease in e cecal isobutyrate. Statistics were completed
using 2-way ANOVA (N = 6-8/group, M:F = 50/50). Error bars show mean ±
SEM, ns = not significant; *p < 0.05; **p < 0.01, ***p < 0.001; ****p < 0.0001.
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Table 3-2 Cecal metabolites – short chain fatty acids
Short Chain
Fatty Acids

E3FAD Control

E3FAD Inulin

E4FAD Control

E4FAD Inulin

Cecal Contents

Concentration
Mean (µg/g)

Concentration
Mean (µg/g)

Concentration
Mean (µg/g)

Concentration
Mean (µg/g)

Acetic Acid

1848  106.1

2817.5  305.4*

1642  213

2614  251.9*

Propionic Acid

394.1  31.6

864  76.2*

312.3  30.7

644.3  50.4*a

Isobutyric Acid

77.2  4.5

37.95  6.8*

64.3  8.5

44.9  5.4

Butyric Acid
2-Methylbutyric
Acid
Isovaleric Acid

590.9  33.3

1575.9  249.4*

521.4  91.1

1083  197.1*

47.9  3.8

37.96  7.8

36.7  4.8

39.3  5.5

47.8  6.5

24.73  8.1*

43.5  7.4

26.3  2.7*

Valeric Acid

78  11.8

70.58  14.4

73.5  12

65.7  3.3

Hexanoic Acid

2.3  0.3

2.81  1.4

1.9  0.4

1.8  0.2
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Table 3-2 Cecal metabolites – short chain fatty acids.
The prebiotic inulin altered short chain fatty acid production in the cecal
contents. Acetic acid, propionic acid, and butyric acid were significantly increased
in the E3FAD and E4FAD mice fed the prebiotic inulin compared to their
respective controls. In contrast, isobutyric acid and isovaleric acid were
significantly decreased. Further, propionic levels in the E4FAD mice fed the
prebiotic inulin were significantly decreased compared to E3FAD mice fed the
prebiotic control. Statistics were completed using 2-way ANOVA (N = 8/group)
with data presented as mean  SEM. *p < 0.05 comparing E3FAD and E4FAD
mice fed the prebiotic inulin to their control fed counterparts; ap < 0.05 comparing
E4FAD mice fed the prebiotic inulin to E3FAD mice fed the prebiotic inulin.
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Figure 3-3 Scyllo-inositol fecal culture experiment
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Figure 3-3 Scyllo-inositol fecal culture experiment
Scyllo-inositol levels in fecal culture. Fecal samples of 7-month old E3FAD
and E4FAD mice (M:F = 50/50) on a standard chow diet were collected and
pooled into their respective groups and fecal cell suspensions were made under
anaerobic conditions. The samples were given either inulin or a control, glucose,
for 24 or 48 hours at which point the supernatant was collected and measured for
scyllo-inositol via NMR. For more details, see Chapter 2, section 2.2. a In fecal
culture, bacteria from the E3FAD mice that were given inulin saw significant
increases in scyllo-inositol compared to those that received the control while
bacteria from E4FAD mice saw an insignificant increase. The E3FAD inulin
culture samples saw a significantly greater increase in scyllo-inositol when
compared to the E4FAD inulin culture samples. Statistics were completed using
2-way ANOVA (groups were run in triplicate). Error bars show mean ± SEM, * p <
0.001 between conditions, # p < 0.05 between groups.
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Figure 3-4 Gut microbiota diversity
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Figure 3-4 Gut microbiota diversity
E3FAD and E4FAD - and -diversity. Fecal samples were collected from
each mouse upon reaching 7-months of age followed by DNA extraction and
amplification. The DNA was then shipped to UIC for 16S rRNA sequencing and
subsequent diversity and taxonomy data analysis. For more details, see Chapter
2, section 2.3. E3FAD mice fed the prebiotic inulin saw a significant difference in
a α- (Gausian link function results, p = 0.00000943) and b β-diversity (ANOSIM R
statistic = 0.877, p-value = 0.001). E4FAD saw no difference in c α- (Gausian link
function results, p = 0.418) but a significant difference in d β-diversity (ANOSIM
R statistic = 0.454, p-value = 0.001) (N = 15/group, M:F = 50/50).
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Table 3-3 Gut microbiota taxonomy
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Table 3-2 Gut microbiota taxonomy
Taxonomic differences at the genus level between E3FAD and E4FAD
prebiotic and control fed mice. Diet and genotype p- and q-values were
calculated for each taxon along with each group. LogFC (log (fold change)) and
LogCPM (base intensity of taxon (log (average counts per million))) were
calculated for each taxon of each group. Diet refers to differences between mice
fed either the prebiotic inulin or control diet. Genotype refers to differences in
FAD mutations with (+) referring to the mice being positive for FAD mutations
and (–) referring to the mice being negative for FAD mutations. The data is
written as a heat map with the darker the respective color indicative of more
significance (N = 15/group, M:F = 50/50).
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Chapter 4

Specific Aim 2: To identify the effects of the prebiotic inulin on

metabolism in the periphery and central nervous system (CNS) between
E3FAD and E4FAD mice.
4.1

Summary
The gut microbiota of APOE4 carriers appears to protect against

foodborne illness and diarrhea in childhood, showcasing the differences that may
be found in the gut microbiota due to genetics. This may also play a role in the
absorption of beneficial metabolites from the gut microbiota into the periphery
and brain between E3FAD and E4FAD mice. We found that the prebiotic inulin is
fermented into beneficial metabolites such as SCFAs and scyllo-inositol in
Chapter 3, which may be able to reach the periphery and potentially generate
effects on the host and reverse metabolic deficits seen in APOE4 carriers.
PURPOSE: The objective of this aim was to identify the effects of the prebiotic
inulin on metabolism in the periphery and central nervous system (CNS) between
E3FAD and E4FAD mice. RESULTS: In the blood, scyllo-inositol was
significantly increased due to the feeding of the prebiotic inulin compared to
control fed animals in E3FAD mice but not in E4FAD mice. Meanwhile, SCFA
levels followed suit to a moderate degree. Metabolites in the blood were also
dramatically different between E3FAD and E4FAD mice fed the prebiotic inulin
compared to controls and between E3FAD and E4FAD mice. This included
tryptophan, tyrosine, pentose pathway, and TCA Cycle metabolites. Next, scylloinositol was dramatically increased in the hippocampus while numerous other
metabolites were also altered in the brain due to the prebiotic inulin. Differences
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were also seen between E3FAD and E4FAD mice in the recently aforementioned
metabolites. CONCLUSIONS: This aim has demonstrated that the beneficial
metabolites that the prebiotic inulin are fermented into in the gut microbiota are
indeed able to reach the bloodstream and brain. However, the levels of these
metabolites that are absorbed into the blood and brain between E3FAD and
E4FAD mice are different, having implications for prevention and treatment of AD
and other pathologies in human APOE3 and APOE4 carriers.
4.2

Introduction
Guerrant et al. have demonstrated that the APOE4 allele may have a

protective effect against foodborne illness and diarrhea in underdeveloped
countries such as in Northeast Brazil, providing a survival advantage [39, 145].
Thus, the gut microbiota of our E3FAD and E4FAD mice may be vastly different
not only in the metabolites they produce from the fermentation of prebiotics, such
as SCFAs and scyllo-inositol as demonstrated in chapter 3, but also in how these
metabolites are absorbed and utilized in the periphery. Based on the literature,
SCFAs can indeed be increased in the circulation [181] and have an impact on
peripheral tissue through direct and indirect modulation of the immune system
[182, 183]. Indeed, the SCFAs have even been found to beneficially impact the
brain through modulation of neuroinflammation [184] and to decrease blood brain
barrier permeability by increasing tight junction proteins [72]. It has been
postulated that butyrate may be able to reach the brain and improve glucose
metabolism and mitochondrial function [148]. Not only this but children
consuming a high fiber diet were found to have better memory and learning
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[185]. However, other gut-brain axis metabolites have also been identified
including tryptophan-derived indole compounds [186]. One such is indole-3propionic acid (IPA), which has been demonstrated to protect neurons via a
reduction in DNA damage and lipid peroxidation [187].
From Chapter 3, we see that the metabolite scyllo-inositol is increased in
the fecal gut microbiota due to the feeding of the prebiotic inulin. This metabolite
has been given as an orally administered therapeutic in AD patients [169] as it is
able to be absorbed into the blood stream, pass through the blood brain barrier
[159], and reach the brain. Indeed, scyllo-inositol has been demonstrated to
decrease Aβ aggregation [159, 164-167] and, for unclear reasons, become
altered in AD patients as evidenced in one neuroimaging study [163]. Altogether,
the gut-brain axis involves a variety of metabolites, many of which may be
unknown, that can benefit the brain and metabolism thereof. However, the
production, absorption, and usage of these beneficial metabolites may vary
between APOE3 and APOE4 carriers. This may be of vast importance as carriers
of the APOE4 allele display an altered brain metabolism and exhibit metabolic
dysfunction via impaired glucose, ketone, and mitochondrial metabolism decades
before the onset of the disease [188]. Further, hypometabolism of the brain has
been exhibited in APOE4 carriers in studies that utilize FDG PET imaging to
measure cerebral metabolic rates of glucose [189] while mitochondrial
dysfunction has also been linked to the disease [190]. Collectively, these
impairments due to the APOE4 allele, dependent and independent of Aβ, lead to
an increased risk to develop AD [191] and we believe that the beneficial
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metabolites from the fermentation of prebiotics may help alleviate these
symptoms.
The objective of this aim was to identify the effects of the prebiotic inulin
on metabolism in the periphery and central nervous system (CNS) between
E3FAD and E4FAD mice. We hypothesized that the prebiotic inulin will
beneficially alter metabolism in the periphery and CNS via increased beneficial
metabolites in E3FAD and E4FAD mice. Specifically, we examined plasma and
hippocampal scyllo-inositol, increased due to feeding of the prebiotic inulin in the
gut microbiota, and metabolites associated with the gut microbiota in the plasma
and brain.

4.3

Results

4.3.1 Plasma Scyllo-Inositol and SCFAs
After demonstrating that scyllo-inositol was indeed formed by gut
microbiota bacteria, we set out to see if scyllo-inositol was absorbed and reached
the bloodstream in our mice. By using NMR, we found that in the plasma of
E3FAD mice that were fed the prebiotic inulin, there was significantly higher
scyllo-inositol levels compared to mice given the control diet, however, this was
not the case in the E4FAD mice. Moreover, the control fed E4FAD mice had a
significant decrease in scyllo-inositol compared to the E3FAD control fed mice
(Fig. 4.1a). SCFA levels in the blood were measured by Metabolon via LCMS/MS, and were also found to be changed, albeit not as significantly as in the
cecal contents, in the mice fed the prebiotic diet. This includes acetate (Fig.
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4.1b), propionate (Fig. 4.1c), and butyrate (Fig. 4.1d). The full panel of SCFAs
are in Table 4.1. Collectively, these results indicate that the prebiotic inulin’s
effect of increasing scyllo-inositol and SCFAs in the gut microbiota can indeed
reach the periphery.

4.3.2 Blood Metabolites
With Metabolon, we found a variety of metabolites in the blood that were
increased due to the prebiotic inulin and differences in blood metabolites
between E3FAD and E4FAD mice (Table 4.2 and Table 4.3). Tryptophan
metabolites were significantly increased due to the prebiotic inulin compared to
controls. These included indoleacrylate, indolepropionate (IPA), serotonin,
indoleacetylglycine, and N-acetyltryptophan in the E3FAD mice fed the prebiotic
inulin and indoleacrylate and IPA in the E4FAD mice fed the prebiotic inulin. In
contrast, tyrosine metabolites were decreased including phenol sulfate and
phenol glucuronide in E3FAD mice fed the prebiotic inulin compared to controls.
In both E3FAD and E4FAD mice fed the prebiotic inulin compared to controls, pcresol glucuronide was decreased. Next, N-acetylglutamine was increased in
mice fed the prebiotic inulin compared to their control diet counterparts. This
metabolite was also increased in E4FAD mice compared to E3FAD mice. Next,
N-acetylhistidine saw a similar result except for no difference in E3FAD fed the
prebiotic inulin compared to their control diet counterpart. N6-methyllysine and Nacetylarginine were also both decreased in E4FAD mice compared to E3FAD
mice.
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Numerous pentose metabolism markers were altered in E4FAD mice fed
the prebiotic inulin compared to controls. This included ribose, increased in both
E3FAD and E4FAD mice fed the prebiotic inulin compared to their respective
controls, while ribitol, ribonate, ribulose, xylose, arabitol, arabonate, and
sedoheptulose were all significantly increased in E4FAD mice fed the prebiotic
inulin compared to controls. The advanced glycation end-product N6carboxymethyllysine was significantly increased due to the prebiotic inulin in
E3FAD and E4FAD mice compared to their control diet counterparts.
In TCA Cycle metabolites, aconitate was increased in E3FAD mice fed the
prebiotic inulin compared to controls while isocitric lactone, alpha-ketoglutarate,
succinate, fumarate, and malate were increased in the E4FAD mice fed the
prebiotic inulin compared to the E4FAD mice fed the control. In contrast,
succinylcarnitine was decreased in both groups due to the prebiotic inulin. Next,
myo-inositol was increased due to the prebiotic inulin in both groups while 2’deoxyuridine was increased in E4FAD mice compared to E3FAD mice. P-cresol
sulfate was also decreased in both groups due to the prebiotic inulin.

4.3.3 Hippocampal Scyllo-Inositol
After reaching the bloodstream, we wanted to confirm that scyllo-inositol is
indeed able to cross the blood brain barrier, as has been reported [159], and
become increased in the brain. Subsets of mice per group (N = 8/group, M:F =
50/50) were randomly chosen for MRS upon reaching 7-months of age. All mice
were anesthetized during the experiment. In both E3FAD and E4FAD mice fed
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the prebiotic inulin compared to controls, scyllo-inositol was drastically increased
in the hippocampus of the brain, a region susceptible to AD pathology (Fig. 4.2a).
An increase in scyllo-inositol was also seen in the E4FAD prebiotic fed mice
compared to the E3FAD prebiotic fed mice. A representative MRS spectra for
each are showcased with the arrow pointing to scyllo-inositol (Fig. 4.2b, Fig. 4.2c,
Fig. 4.2d, Fig. 4.2e). These results indicate that the prebiotic inulin’s effect of
increasing scyllo-inositol in the gut microbiota and plasma can reach the
hippocampus of the brain and provide dramatic increases in both E3FAD and
E4FAD mice. However, the E4FAD mice fed the prebiotic diet saw an even
greater increase in scyllo-inositol compared to E3FAD mice fed the prebiotic diet,
indicative that the E4FAD mice may have less scyllo-inositol absorbed from the
gut but greater absorption into the brain. Whether this effect is a protective
mechanism in E4FAD mice, as scyllo-inositol has not only been determined to
inhibit Aβ aggregation but also provide an anti-inflammatory effect, albeit likely
from the inhibition of Aβ [165], remains to be seen.

4.3.4 Brain Metabolites
The prebiotic inulin altered numerous brain metabolites (Table 4.4),
measured by Metabolon, in both E3FAD and E4FAD mice. There were also
differences between E3FAD and E4FAD mice themselves. Firstly, Nacetylglutamine, N-acetylhistidine, homocarnosine, N-acetylphenylalanine, Nacetyltyrosine, N-acetylglucosaminylasparagine, palmitoleoyl ethanolamine,
glycerophosphoinositol, 1-(1-enyl-palmitoyl)-2-palmitoleoyl-GPC, 2’deoxyuridine,
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ascorbate, and pyridoxamine were significantly increased in E4FAD mice
compared to E3FAD mice. In contrast, N6-methyllysine, 2-aminoadipate, Nacetylarginine, mannonate were decreased in E4FAD mice compared to E3FAD
mice. The prebiotic inulin caused an increase in imidazole propionate, N6carboxymethyllysine, acetylcarnitine, and scyllo-inositol in both groups. In
contrast, the prebiotic inulin caused a decrease in myo-inositol and p-cresol
sulfate.
4.4

Discussion
In Chapter 3, we saw that scyllo-inositol was drastically increased during

our fecal culture experiment, especially so in E3FAD mice. The next step was
seeing if these changes could reach the blood stream. We see that in the plasma
of E3FAD mice fed the prebiotic inulin, scyllo-inositol is indeed significantly
increased compared to controls. However, there was no difference seen in the
E4FAD mice. In fact, even when comparing E3FAD and E4FAD mice fed the
control diet, scyllo-inositol was significantly greater in the E3FAD mice. It is
possible that the level of scyllo-inositol in the plasma may be somewhat
dependent on when the mice eat and when that food is fermented and absorbed
into the bloodstream and this may have impacted the results seen in the E4FAD
mice. However, it is more likely that less scyllo-inositol is absorbed from the gut
by E4FAD mice compared to E3FAD mice for reasons that are currently unclear
but has important implications for APOE4 carriers. This could even be due to
receptor or transporter differences in the gut or perhaps scyllo-inositol is binding
to metabolites or other metabolic products that are produced more so in E4FAD
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mice with subsequent clearance via the fecal matter. Our next step was to see if
scyllo-inositol was able to be increased in the brain, specifically in the
hippocampus, a region susceptible to AD pathology and important for learning
and memory [192]. In fact, we saw a dramatic increase in hippocampal scylloinositol in both E3FAD and E4FAD mice that were fed the prebiotic inulin with the
E4FAD mice having an even greater increase. In Chapter 3, we saw that the
E4FAD mice had an increase in scyllo-inositol in the fecal culture experiment but
to a lesser extent than the E3FAD mice fed the prebiotic inulin. Further, previous
results in this chapter indicated that less scyllo-inositol is being produced by the
gut microbiota and absorbed into the blood in E4FAD mice fed the prebiotic inulin
compared to E3FAD mice fed the prebiotic inulin. Despite this, it appears that
scyllo-inositol is taken into the brain at a higher rate in E4FAD mice compared to
E3FAD mice. When comparing E3FAD and E4FAD mice fed the control, there
was no significant difference in scyllo-inositol although there was a slight
increase in E4FAD mice compared to the E3FAD mice. Notably, scyllo-inositol
has been demonstrated before to be increased in AD patients [163]. We suspect
this may be due to a compensatory mechanism in an attempt to decrease
inflammation and halt A aggregation in the brain in APOE4 carriers. Due to the
fact that scyllo-inositol has been demonstrated to inhibit A aggregation and
through this, decrease inflammation, these outcomes will be further explored in
Chapter 5. Nevertheless, these results are quite intriguing and deserve further
attention as to why APOE4 carriers may have differences in production and
absorption of certain metabolites into the periphery and brain.
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In Chapter 3, we also saw that the SCFAs were dramatically increased in
the cecal contents and we wanted to see if these metabolites were absorbed into
the bloodstream. Here, we do see that the prebiotic inulin increased SCFAs in
the bloodstream but to a much lesser degree than that of the cecal contents.
There are a number of reasons for this. Firstly, SCFAs can be taken up by
colonocytes and especially in the case of butyrate, used as an important energy
source [154]. Next, the liver takes up and clears SCFAs in the portal circulation
as too high of levels may become toxic. Here in the liver, the SCFAs can act as
precursors to other processes. The SCFAs can also activate G protein-coupled
receptors, such as Ffar2 and Ffar3, that help regulate glucose and lipid
metabolism and can be found on immune cells [154]. Receptors expressed by
other organs are likely present, but little is known about them at this time. Finally,
SCFAs can also simply be excreted through the fecal contents [154]. Whether
this increase in the bloodstream leads to a decrease in AD pathology is a
question that will be addressed in the next chapter.
We next looked a variety of other metabolites that were altered in the
whole blood of our mice and saw vast differences. Firstly, dramatic changes were
seen in tryptophan and tyrosine metabolism, especially in our E3FAD mice fed
the prebiotic inulin. Indeed, indoleacrylate, IPA, serotonin, indoleacetylglycine,
and N-acetyltryptophan were all increased in E3FAD mice while only
indoleacrylate and IPA were increased in E4FAD mice. In fact, even more
dramatic increases were seen in the E4FAD mice in these two metabolites.
Tryptophan metabolism in the gut includes metabolization of tryptophan to either
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kynurenine, serotonin, and/or indole pathways, the latter two shown here. The
serotonin pathway is important as 90% of serotonin is produced in the gut,
although peripheral serotonin does not often cross the BBB but may
communicate with the CNS nonetheless [193] and activate receptors in the gut
that increase satiety and absorption of nutrients [194]. Although much is not
understood about this process, SCFAs have been implicated in initiating
serotonin biogenesis. Due to the increase in SCFAs we saw in the cecal
contents, this increase in serotonin would make sense here although there was
only a significant increase in serotonin in E3FAD mice fed the prebiotic inulin.
Further, IPA, a part of the indole pathway through tryptophan metabolism, has
been shown to inhibit A aggregation [85] and here we see that the prebiotic
inulin can indeed increase this metabolite in both groups. Next, metabolites that
play a role in tyrosine metabolism were decreased due to the prebiotic inulin
including phenol sulfate, phenol glucuronide, and p-cresol glucuronide in E3FAD
mice. E4FAD mice fed the prebiotic inulin only saw a decrease in p-cresol
glucuronide. One study using resistant maltodextrin in mice found a decrease in
both phenol sulfate and p-cresol sulfate, linking them both to inflammation [195].
Bacteroides, which we saw decreased in E3FAD mice fed the prebiotic inulin,
has been linked to their production, however, Bifidobacterium has been linked as
well [196]. Overall, there is surprisingly little known on tyrosine metabolites and
we hope our results shed some light on this matter. Collectively, it appears that
the prebiotic inulin increases tryptophan metabolism in the gut microbiota while
decreasing tyrosine metabolism.
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Next in the blood, we found that N-acetylglutamine and N-acetylhistidine
were both increased in the E4FAD mice compared to the E3FAD mice with the
prebiotic inulin increasing N-acetylglutamine in both E3FAD and E4FAD mice.
N6-methyllysine and N-acetylarginine were decreased in the E3FAD mice
compared to E4FAD mice. Next, N6-carboxymethyllysine was increased in both
E3FAD and E4FAD mice fed the prebiotic inulin compared to controls. Due to the
prebiotic inulin, myo-inositol was increased in both groups while in the E4FAD
mice compared to E3FAD mice, it was also increased. 2’-deoxyuridine saw a
decrease in E3FAD mice fed the prebiotic inulin but an increase in E4FAD mice
compared to E3FAD mice. Finally, p-cresol sulfate saw significant decreases in
both E3FAD and E4FAD mice fed the prebiotic inulin. Little is known on these
metabolites aside from the aforementioned myo-inositol and p-cresol sulfate.
A variety of metabolites involved in Pentose Phosphate Pathway (PPP)
metabolism, responsible for NADPH production, were dramatically increased in
the E4FAD mice fed the prebiotic inulin compared to E4FAD control mice. This
includes ribose, ribitol, ribonate, ribulose, xylose, arabitol, arabonate, and
sedoheptulose. Ribonate, xylose, and sedoheptulose were increased in the
E4FAD mice compared to E3FAD mice. It is not currently known why E4FAD
mice fed the prebiotic inulin would have such increases in these metabolites
while the E3FAD mice fed the prebiotic inulin do not. However, one study did find
an increase in the PPP linking it as a way for neurons to get energy as an
alternative to glucose [27] as APOE4 carriers do indeed have hypometabolism
and alterations in glucose metabolism. This paper further postulated that
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changes in the PPP may be a novel target that connects APOE4 to changes in
glucose metabolism and oxidative stress. Further confirming this idea, we also
found changes in the TCA cycle especially in E4FAD mice fed the prebiotic inulin
with significant increases in isocitric lactone, alpha-ketoglutarate, succinate,
fumarate, and malate compared to E4FAD mice fed the control. In contrast, a
significant decrease was seen in succinylcarnitine. The E3FAD mice fed the
prebiotic inulin only saw significant increases in aconitate and alphaketoglutarate but also an insignificant decrease in succinylcarnitine. Similar to the
changes found in E4FAD mice fed the prebiotic inulin in the PPP, we see large
changes in the TCA cycle, indicative of altered glucose metabolism. Again, it is
unusual that there were so few differences between the E3FAD and E4FAD mice
themselves especially given that it is known that APOE4 carriers have alterations
in glucose metabolism. It is quite unclear why the prebiotic inulin would be
causing such dramatic effects in only E4FAD mice fed the prebiotic inulin, but we
hope this is indicating that the prebiotic inulin is decreasing the hypometabolism
and metabolic alterations that occur in APOE4 carriers as they age.
Our results indicate that numerous markers were altered in the brain due
to the prebiotic inulin and differences between E3FAD and E4FAD mice were
also present. Firstly, N-acetylglutamine, N-acetylhistidine, homocarnosine, Nacetylphenylalanine, N-acetyltyrosine, N-acetylglucosaminylasparagine,
palmitoleoyl ethanolamine, glycerophosphoinositol, 1-(1-enyl-palmitoyl)-2palmitoleoyl-GPC, 2’deoxyuridine, ascorbate, and pyridoxamine were
significantly increased in E4FAD mice compared to E3FAD mice. N-acetyl amino
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acids have been found to be altered in the gut microbiota when compared to
germ-free mice [197]. In contrast, N6-methyllysine, 2-aminoadipate, Nacetylarginine, mannonate were decreased in E4FAD mice compared to E3FAD
mice. The prebiotic inulin caused an increase in imidazole propionate, N6carboxymethyllysine, acetylcarnitine, and scyllo-inositol in both groups. In
contrast, the prebiotic inulin caused a decrease in myo-inositol and p-cresol
sulfate. Many of these differences were also present in the blood of the mice.
Myo-inositol was increased in the blood due to the prebiotic inulin in both groups
but decreased in the brain while scyllo-inositol, confirming the MRS findings in
this chapter, was increased in both groups as well. Myo-inositol is thought to be
increased in the asymptomatic stages of AD [198] but scyllo-inositol treatment
has been shown to decrease its levels and improve neuropsychiatric symptoms
[199]. In one study, Yamashita et al. believed it was possible that myo-inositol
could be converted to scyllo-inositol in blood and skeletal muscle [161] but the
evidence was fairly weak. Further, due to the increases in scyllo-inositol seen in
the gut and blood of our mice fed the prebiotic inulin, this seems unlikely to be a
major cause of the scyllo-inositol increase seen here in the brain. P-cresol sulfate
was decreased in both groups due to the prebiotic inulin in both the blood and
brain and has been linked to inflammation [195]. In contrast, N6carboxymethyllysine, an advanced glycation-end product, was increased in both
groups in the blood and brain due to the prebiotic inulin. While this could be
considered a new gut-brain axis component, advanced glycation-end products
have been implicated in diabetes [200]. This metabolites role in the brain is
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unknown. N-acetylglutamine was increased due to the prebiotic inulin in both
groups in the blood but not in the brain. Meanwhile, E4FAD mice also saw an
increase in this metabolite in both the blood and brain compared to E3FAD mice.
Finally, N-acetylhistidine, N-acetylarginine, and N6-methyllysine were decreased
in both the blood and brain in E4FAD mice compared to E3FAD mice. However,
little is known about these metabolites.
Collectively, the prebiotic inulin caused a vast array of metabolic changes
in the blood and brain of both E3FAD and E4FAD mice fed the prebiotic inulin
compared to controls while changes between E3FAD and E4FAD mice were also
evident. It is also notable that the prebiotic inulin was able to enhance the
metabolism of multiple GBA components: SCFAs, IPA, and the newly discovered
scyllo-inositol. Whether these changes will make an impact in the brain and
decrease AD pathology will be the subject of Chapter 5.
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Figure 4-1 Plasma scyllo-inositol and SCFAs
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Figure 4-1 Plasma scyllo-inositol and SCFAs
Plasma scyllo-inositol and SCFAs. E3FAD and E4FAD mice were
sacrificed at around 7-months of age with plasma and whole blood collected.
Plasma scyllo inositol was measured via NMR. More details can be found in
Chapter 2, section 2.4. For blood SCFA measurement, Metabolon utilizes LCMS/MS. More details can be found in Chapter 2, section 2.5. a Scyllo-inositol in
the plasma of E3FAD and E4FAD mice found a significant increase between
E3FAD mice fed the prebiotic inulin and their respective control group. Plasma
scyllo-inositol levels were also significantly increased in E3FAD mice compared
to E4FAD mice. b Other metabolites increased due to the prebiotic diet include
the SCFAs butyrate, propionate, and acetate but the only significant increase
was acetate in the E3FAD mice fed the prebiotic inulin compared to their
respective control group. Statistics were completed using 2-way ANOVA (For
plasma scyllo-inositol measurement, N = 10/group (M:F = 50/50) and for SCFA
measurement, N = 8/group (M:F = 50/50). Error bars show mean ± SEM, ns =
not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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Table 4-1 Blood metabolites – short chain fatty acids
Short Chain Fatty
Acids

Concentration
Mean (ng/mL)

E4FAD
Control
Concentration
Mean (ng/mL)

Concentration
Mean (ng/mL)

2290  490.9

5012.5  1274.9

1918  261.1

6632  1410.3*

Propionic Acid

112.6  20.6

242.9  73.3

82  10.3

145.9  31.9

Isobutyric Acid

35.3  4.7

35.6  4.8

25.4  3

29.9  5.2

Butyric Acid

157.9  20.5

257.1  96

144.4  33.9

222.6  22.7

2-Methylbutyric Acid

24.6  3.5

27.7  3.6

20.8  2.9

31.8  7.3

Isovaleric Acid

8.8  1.9

7.1  1

8.6  1.5

6.7  1.9

Valeric Acid

10  3.3

10.8  3.5

5.4  1.9

12.6  5.7

Hexanoic Acid

51.9  5.7

42.3  6.7

60.9  17

70.4  11.6

E3FAD Control

E3FAD Inulin

Blood

Concentration
Mean (ng/mL)

Acetic Acid
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E4FAD Inulin

Table 4.1 Blood metabolites – short chain fatty acids
A table showcasing the levels of short chain fatty acids in the blood.
E4FAD mice fed the prebiotic inulin saw a significant increase in propionic acid
compared to E4FAD mice fed the control diet. Statistics were conducted using 2way ANOVA (N = 8/group, M:F = 50/50) with data presented as mean  SEM. *p
< 0.05.
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Table 4-2 Blood metabolites – tryptophan and tyrosine metabolism
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Table 4-2 Blood metabolites – tryptophan and tyrosine metabolism
A table showcasing the changes in tryptophan and tyrosine metabolites,
and other select metabolites, due to the prebiotic inulin and differences between
E3FAD and E4FAD mice in the blood. The whole blood of the mice was sent to
Metabolon (Durham, NC) for metabolomic profiling. For more details, see
Chapter 2, section 2.5. Heat map of statistically significant biochemicals profiled
when comparing groups are labeled as follows: A dark red box indicates that p <
0.05 and the group means fold of change > 1.00. A dark green box indicates that
p < 0.05 and the group means fold of change < 1.00. A light red box indicates
that 0.05 < p < 0.10 and group means fold of change > 1.00. A light green box
indicates that 0.05 < p < and group means fold of change < 1.00 (N = 8/group,
M:F = 50/50).
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Table 4-3 Blood metabolites – pentose metabolism and TCA cycle
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Table 4.3 Blood metabolites – pentose metabolism and TCA cycle
A table showcasing the changes in pentose and TCA cycle metabolites,
and other select metabolites, due to the prebiotic inulin and differences between
E3FAD and E4FAD mice in the blood. The whole blood of the mice was sent to
Metabolon (Durham, NC) for metabolomic profiling. For more details, see
Chapter 2, section 2.5. Heat map of statistically significant biochemicals profiled
when comparing groups are labeled as follows: A dark red box indicates that p <
0.05 and the group means fold of change > 1.00. A dark green box indicates that
p < 0.05 and the group means fold of change < 1.00. A light red box indicates
that 0.05 < p < 0.10 and group means fold of change > 1.00. A light green box
indicates that 0.05 < p < and group means fold of change < 1.00 (N = 8/group,
M:F = 50/50).
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Figure 4-2 Hippocampal scyllo-inositol
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Figure 4-2 Hippocampal scyllo-inositol
Hippocampal scyllo-inositol. Scyllo-inositol in the hippocampus was
measured via MRI when the mice reached 7-months of age. Specifically, MRS
was utilized while the mice were anaesthetized. For more details, see Chapter 2,
section 2.6. a Scyllo-inositol was dramatically increased in the hippocampus of
inulin-fed E3FAD and E4FAD mice compared to controls. Both groups of E4FAD
mice saw a significant increase in scyllo-inositol when compared to their diet
counterparts. Representative spectra are shown for (b) E3FAD Control, (c)
E3FAD inulin, (d) E4FAD Control, and (e) E4FAD inulin groups with the arrow
pointing to scyllo-inositol. Statistics were completed using 2-way ANOVA (N =
8/group, M:F = 50/50). Error bars show mean ± SEM, ns = not significant; *p <
0.05; **p < 0.01.
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Table 4-4 Brain metabolites
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Table 4-4 Brain metabolites
Mice fed the prebiotic diet had altered metabolites in the brain. Differences
between E3FAD and E4FAD mice were also present. Upon sacrifice around 7months of age, the brains of the E3FAD and E4FAD mice were collected
followed by being shipped to Metabolon (Durham, NC) for metabolomics. Heat
map of statistically significant biochemicals profiled when comparing groups are
labeled as follows: A dark red box indicates that p < 0.05 and the group means
fold of change > 1.00. A dark green box indicates that p < 0.05 and the group
means fold of change < 1.00. A light red box indicates that 0.05 < p < 0.10 and
group means fold of change > 1.00. A light green box indicates that 0.05 < p <
and group means fold of change < 1.00 (N = 8/group, M:F = 50/50).
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Chapter 5

Specific Aim 3: To identify the effects of the prebiotic inulin on

AD risk factors and pathology between E3FAD and E4FAD mice.
5.1

Summary
AD is a progressive neurodegenerative disorder with Aβ aggregation and

increased inflammation being two major hallmarks of the disease. APOE4
carriers are particular susceptible to these hallmarks and have an increased risk
of AD development compared to APOE3 carriers. However, the gut microbiota is
able to ferment prebiotics such as inulin into metabolites, as seen in previous
chapters, that can provide benefits to the brain, potentially decreasing AD risk
factors and pathology in APOE4 carriers. PURPOSE: To identify the effects of
the prebiotic inulin and the associated generated metabolites on AD risk factors
and pathology between E3FAD and E4FAD mice compared to their respective
control diet counterparts. Further, to compare E3FAD and E4FAD mice.
RESULTS: The prebiotic inulin did not change CBF, amyloid- aggregation, or
anxiety and spatial recognition, working, and reference memory. However,
markers of inflammation revealed significant differences due to the prebiotic
inulin. CONCLUSIONS: The prebiotic inulin was able to decrease AD risk factors
in E4FAD mice by decreasing certain markers of inflammation. Thus, utilizing the
prebiotic inulin, displaying effects likely via beneficial metabolites produced from
its fermentation in the gut, as a preventative measure may be one way to
diminish inflammation and help decrease AD risk factors.
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5.2

Introduction
AD is a progressive neurodegenerative disorder with a variety of

symptoms that include memory loss and the inability to learn new things [201],
decreased cerebral blood flow [202], and increased inflammation and Aβ
aggregation [203]. This is especially true in APOE4 carriers who exhibit
decreased CBF and increased BBB permeability via the activation of the
inflammatory cyclophilin A-nuclear factor-κB-matrix-metalloproteinase-9 pathway
[20]. Further, APOE4 carriers do indeed have increased amyloid deposition as
evidenced in humans [204] and in APOE4 transgenic mice [205]. APOE4 carriers
also appear to have increased inflammation. In one study displaying this in
APOE4 transgenic mice, the APOE4 mice were demonstrated to have increased
inflammation, via increased microglial and NF-κB gene expression, compared to
APOE3 mice [206]. It is also thought that the increase in Aβ aggregation may
also increase inflammation [207]. However, the gut microbiota and associated
metabolites have literature that support the potential reversal of these symptoms,
discussed next.
The prebiotic inulin is fermented into a variety of metabolites that can
benefit the brain by potentially decreasing AD pathology. Firstly, scyllo-inositol,
increased due to feeding of the prebiotic inulin in Chapter 3, has been
demonstrated to inhibit Aβ aggregation in in vivo and in vitro trials [159, 164-167].
It is thought that through this inhibition, scyllo-inositol also decreases
inflammation [165]. Next, SCFAs produced from the fermentation of the prebiotic
inulin, also seen in Chapter 3, decrease BBB permeability through the increase

104

of BBB tight junction proteins [72]. The SCFAs can also modulate the immune
system through a variety of ways. One study found that SCFAs were able to
suppress Th17 cell production, promote Treg cells from CD4 + naive T cells, and
activate the lipin2-JIP2 pathway, all subduing inflammation [208]. They also help
regulate T cell size and function in the colon [209]. Further, SCFAs can act as
histone deacetylase (HDAC) inhibitors, further promoting an anti-inflammatory
effect [210]. Specifically, sodium butyrate has been used in an AD mouse model
to restore histone acetylation activity with effects reaching the brain as genes
associated with learning and memory were upregulated [211].
The objective of this aim was to identify the effects of the prebiotic inulin
on AD risk factors, including CBF, inflammation, anxiety, and cognition, and Aβ
aggregation between E3FAD and E4FAD mice. We hypothesized that the
prebiotic inulin will decrease AD risk factors and Aβ aggregation in E3FAD and
E4FAD mice. Specifically, we examined the differences between E3FAD and
E4FAD mice and the effect of the prebiotic inulin on CBF, inflammation,
metabolism, anxiety and cognition, and Aβ aggregation. This is the pay-off
chapter from all our previous work!

5.3

Results

5.3.1 Cerebral Blood Flow
Subsets of mice per group (N = 8-10/group, M:F = 50/50) were randomly
chosen to undergo MRI. Specifically, PCASL was utilized to measure CBF while
the mice were anesthetized. Due to CBF being decreased with age [212] and in
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AD [213], we anticipated the prebiotic inulin may be able to impact CBF.
However, this was not the case as the prebiotic inulin found no effect on cerebral
blood flow in the hippocampus of the brain compared to controls. There were
also no differences between E3FAD and E4FAD mice.
5.3.2 Amyloid-β Aggregation
In multiple in vivo and in vitro studies, scyllo-inositol has been
demonstrated to inhibit Aβ aggregation [159, 164-167]. We took a subset of
brains from each group of E4FAD mice when the mice were sacrificed at around
7-months of age for Aβ staining (N = 5/group, M:F = 50/50). These were sent to
the COCVD Pathology Research Core at the University of Kentucky to be
embedded and sectioned onto microscope slides. Immunohistochemistry was
then performed for identification of Aβ followed by a background stain utilizing
NISSL. After the slides were imaged via the Aperio ScanScope XT Digital Slide
Scanner System in the University of Kentucky Alzheimer’s Disease Center and
uploaded to the online database, Aperio ImageScope was used to analyze total
anti-Aβ counts. We found that the prebiotic inulin had no effect on amyloid
deposits in E4FAD mice (Fig. 5.1a with 5.1b and 5.1c as representative images
of each group). These results indicate that the increase in scyllo-inositol due to
the prebiotic inulin was unable to inhibit Aβ aggregation. Perhaps if the prebiotic
inulin was given for a longer period of time, effects may have been evident.
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5.3.3 NanoString Array
E4FAD mice were sacrificed around 7-months of age with the brains
collected and hippocampus dissected. Next, RNA was isolated and then
quantified via the NanoString array. Specifically, we first wanted to see if the FAD
mutations and/or the prebiotic inulin are able to alter markers of inflammation in
the brain. This was completed by looking at 561 gene targets, with 318 genes
being above the background threshold. When comparing the differential
expression between APOE4 mice with and without the FAD mutations, 52 genes
were significantly enriched by greater than one Log2 fold change (Fig. 5.3a).
Among these 52 genes in E4FAD mice, we next wanted to examine the effect of
the prebiotic inulin on these 52 genes via the mean Log2 difference between
E4FAD mice fed either the prebiotic inulin or control diet. Among the 52 genes, 4
genes had around a 2-fold decrease in expression due the prebiotic inulin (Fig.
5.3b). Two of these genes were significantly decreased while 2 of the genes
were insignificantly decreased due to the prebiotic inulin. The two significantly
decreased genes were chemokine (C-C motif) ligand 4 (CCL4) (Fig. 5.3c) and Fc
receptor IgG low affinity 4 (Fcgr4) (Fig. 5.3f) while the insignificantly decreased
genes were C-X-C motif chemokine 10 (CXCL10) (Fig. 5.3d) and integrin alpha X
(Itgax) (Fig. 5.3e).

5.3.4 Animal Behavior Tests
We wanted to measure the impact of the prebiotic inulin on multiple animal
behavior tests. At 7-months of age, E3FAD and E4FAD mice underwent behavior
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testing over a two-week period starting at the same time each morning. The
behavior tests included elevated plus maze, evaluating the anxiety of mice, open
field test, evaluating the anxiety of the mice in a new environment, novel object
recognition, testing spatial recognition memory, and radial arm water maze,
testing both spatial working and reference memory. When looking at radial arm
water maze (Fig. 5.4a), no difference was seen between mice fed the prebiotic
inulin and control diet. This also held true for the open field test (Fig. 5.4b),
elevated plus maze (Fig. 5.4c), and novel object recognition test (Fig. 5.4d).
Differences were also not apparent between E3FAD and E4FAD mice.
5.4

Discussion
As one ages, a decline in CBF occurs [212] and in APOE4 carriers, a

decline is even seen before other AD-like symptoms occur [19]. Bell et. al.
demonstrated that the breakdown of the BBB due to the APOE4 allele may be
responsible for this decline in CBF [20]. Interestingly, SCFAs have been
demonstrated to impact the BBB [72] and with the increase of SCFAs in the
periphery due to the prebiotic inulin, we anticipated an increase in CBF. Although
it is difficult to draw definitive conclusions, we did not see a difference in CBF due
to the prebiotic inulin. However, there were also no differences between E3FAD
and E4FAD mice as we expected to see a decrease in E4FAD mice compared to
E3FAD mice. This may indicate that the deficits in CBF that APOE4 is thought to
invoke may not have occurred yet, perhaps due to the mice not being advanced
enough in age.
We next looked at the effect of the prebiotic inulin on amyloid aggregation.
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In E4FAD mice that were fed either the prebiotic or control diet, there were no
differences between groups. Due to the increases in GBA components because
of the prebiotic inulin, we suspected that the prebiotic fed mice may see a
significant decrease in A aggregation. However, this was not the case as no
differences were seen between groups in E4FAD mice. If the mice had begun
being fed before they reached 3-months of age or if we allowed the study to go
for a longer period of time, perhaps the effects of the prebiotic inulin would have
been more pronounced.
However, we do see that the prebiotic inulin was able to change markers
of inflammation. Firstly, the effect of the FAD mutations in APOE4 mice was
analyzed. Mice with FAD mutations have been demonstrated in the literature to
have increases in inflammatory markers [214] and this was further confirmed
here. Among the 52 genes that were shown to be altered due to the FAD
mutations, there was a noticeable downward trend in the E4FAD mice fed the
prebiotic inulin compared to the control group. Specifically, significant decreases
were seen in CCL4 and Fcgr4 while insignificant decreases were seen in
CXCL10 and Itgax. CCL4 is a chemokine that has been found to be increased in
mice with the APP/PS1 mutations and has been associated with the progression
of A in the brain [215] while also being altered in human APOE4 carriers [216].
Fcgr4, along with other Fcgr’s, have been found to potentially stimulate vascular
damage and neurodegeneration while also being upregulated due to increased
systemic inflammation, neuroinflammation, and aging [217, 218]. Next, CXCL10
is a chemokine found in high concentrations in certain AD mouse models and
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even in AD patients [219, 220]. In fact, cerebrospinal fluid CXCL10
concentrations have been positively correlated with cognitive impairment [221].
Notably, the receptor of CXCL10 is CXCR3 and in one study using CXCR3deficient APP/PS1 mice, A and plaque burden were greatly reduced along with
a decrease in behavioral impairment, showcasing the importance of this pathway
in AD disease progression [219]. Finally, Itgax is an integrin protein that appears
to be induced in microglia in AD [222] but is actually downregulated in APOE
knock-out APP/PS1 mice [223]. Since inflammation is notably increased in AD
and is an important aspect of AD pathology [224], the decrease in inflammatory
genes seen here, especially those that appear to play a role in AD pathology and
progression, due to the prebiotic inulin may be a convenient, translatable way for
a nutritional intervention to decrease AD pathology over time.
Finally, we wanted to see if the prebiotic inulin was able to impact animal
behavior tests. Increased anxiety is thought to be a symptom preceding AD [225]
and diminished mental capabilities and cognition are AD symptoms [1]. Firstly,
we did not see any differences in the elevated plus maze or open field test, two
tests measuring the anxiety of the mice. Further, we saw no differences in radial
arm water maze and novel object recognition test, tests that measure spatial
working and reference memory, and spatial recognition memory, respectively.
Oddly, we also saw no differences between E3FAD and E4FAD mice. In fact, Liu
et. al. found behavior deficits via the Morris Water Maze, assesses spatial
working and reference memory, and Y-maze, assesses spatial recognition
memory, when comparing 6-month old E4FAD mice to E3FAD mice although the
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effects were quite modest [33]. Nevertheless, perhaps if our mice were older we
would have seen more deficits in cognition between E3FAD and E4FAD mice
and more of an impact from the prebiotic inulin.
Collectively, the prebiotic inulin was able to decrease markers of
inflammation but was unable to effect CBF, A aggregation, or any animal
behavior tests. Notably, there were also no differences between E3FAD and
E4FAD mice in CBF or any of the behavior tests. This may indicate the mice
were not old enough to develop deficits in CBF, anxiety, and/or spatial working,
reference, or recognition memory. Effects may also have been more apparent if
the sample size was larger in certain experiments. Nevertheless, the prebiotic
inulin was able to decrease markers of inflammation, which we believe over time
may help decrease AD risk factors and pathology.
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Figure 5-1 Hippocampal cerebral blood flow
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Figure 5-1 Hippocampal cerebral blood flow
The prebiotic inulin did not impact CBF in the hippocampus. Subsets of
mice per group were randomly chosen upon reaching 7-months of age to
undergo MRI. Specifically, PCASL was utilized to measure CBF while the mice
were anesthetized. For more details, see Chapter 2, section 2.6. a E3FAD and
E4FAD mice fed the prebiotic inulin did not see differences when compared to
their control fed counterparts. Further, there were no differences between E3FAD
and E4FAD mice. Statistics were conducted using 2-way ANOVA (N = 810/group, M:F = 50/50). Error bars show mean ± SEM. ns = not significant.
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Figure 5-2 Amyloid- staining
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Figure 5-2 Amyloid- staining
Aβ staining in the brains of E4FAD mice. The mouse brains were collected
upon sacrifice around 7-months of age and sent to the COCVD Pathology
Research Core at the University of Kentucky to be embedded and sectioned onto
microscope slides. Immunohistochemistry was then performed for identification
of Aβ followed by a background stain utilizing NISSL. After the slides were
imaged via the Aperio ScanScope XT Digital Slide Scanner System in the
University of Kentucky Alzheimer’s Disease Center and uploaded to the online
database, Aperio ImageScope was used to analyze total anti-Aβ counts. For
more details, see Chapter 2, section 2.7. a E4FAD mice fed the prebiotic diet did
not see differences in Aβ aggregation (percent load) in the brain. b
Representative image of E4FAD mice fed the control diet. c Representative
image of E4FAD mice fed the prebiotic diet. Statistics were conducted using 2way ANOVA (N = 5/group, M:F = 50/50). Error bars show mean ± SEM. ns = not
significant.
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Figure 5-3 NanoString array analysis
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Figure 5-3 NanoString array analysis
The impact of the FAD mutations and prebiotic inulin on markers of
inflammation. E4FAD mice were sacrificed around 7-months of age with the
brains collected and hippocampus dissected. Next, RNA was isolated and then
quantified via the NanoString array. For more details, see Chapter 2, section 2.8.
a In APOE4 mice with and without the FAD mutations, data are plotted as the
mean ratio expression with their respective adjusted p-value. This revealed 52
genes that were significantly differentially enriched (magenta) with greater than
one Log2 fold change due to the FAD mutations. b The 52 genes that were
enriched due to the FAD mutations were further examined under the context of
diet manipulation. Overall, there was a trend for most of the 52 genes to be
downregulated due to the prebiotic inulin in E4FAD mice. Further, a 2-fold
decrease in expression was seen in 4 genes (aquamarine). Among these, c
CCL4, and f Fcg4 were significantly decreased and d CXCL10 and e Itgax were
insignificantly decreased due to the prebiotic inulin. Statistics were completed
using 2-way ANOVA (Sidak posthoc multiple comparisons correction) (N =
5/group, all male). For more details, see section 2.8. Error bars show mean ±
SEM, ns = not significant; *p < 0.05.
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Figure 5-4 Behavior tests
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Figure 5-4 Behavior tests
The impact of the prebiotic inulin on animal behavior tests. At 7-months of
age, E3FAD and E4FAD mice underwent behavior testing over a two-week
period starting at the same time each morning. The behavior tests included
elevated plus maze, evaluating the anxiety of mice, open field test, evaluating the
anxiety of the mice in a new environment, novel object recognition, testing spatial
recognition memory, and radial arm water maze, testing both spatial working and
reference memory. For more details, see section 2.9. In E3FAD and E4FAD mice
fed the prebiotic inulin compared to their control fed counterparts and when
comparing E3FAD and E4FAD mice, no differences were seen in a radial arm
water maze, b open field test, c elevated plus maze, or d novel object
recognition. All behavior tests were conducted in the Rodent Behavior Center at
the University of Kentucky when the mice reached 7-months of age. Statistics
were conducted using 2-way ANOVA (N = 7-9/group, M:F = 50/50). Error bars
show mean ± SEM. ns = not significant.
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Chapter 6
6.1

General Discussion

Discussion
This project uncovered many remarkable findings that will prove to be

impactful in the field. Firstly, we see that the prebiotic inulin is able to significantly
alter the gut microbiota in both E3FAD and E4FAD mice. Not only this but the
response of the mice to the prebiotic inulin was different to where E3FAD mice
appear to gain more benefit than do E4FAD mice. This includes greater
increases in beneficial taxa such as Bifidobacteria, Lactobacillus, and
Akkermansia in the E3FAD mice. Interestingly, we found that due to the prebiotic
inulin, scyllo-inositol was increased by the fecal microbiota population and that
the SCFAs levels were also considerably higher in the cecal contents.
Amazingly, the E4FAD mice fed the prebiotic inulin had less of an increase in
scyllo-inositol, propionate, and butyrate than did the E3FAD mice fed the
prebiotic inulin, indicative that the gut microbiota of E4FAD mice are unable to
produce as much beneficial metabolites. Due to work by Dr. Richard Guerrant
where children who were APOE4 carriers were more resistant to enteric infection
and thus had improved cognition [226], our lab thought E4FAD mice in our study
may have a more beneficial gut microbiota. We did not come to such a
conclusion based on our data but the benefits of the APOE4 allele during
development have been well noted in the literature [227]. Nevertheless, it is
possible that the gut microbiota of APOE4 carriers is resistant to enteric infection
but for reasons we have yet to understand. Further, the gut of APOE4 carriers
may need a higher dosage of prebiotics to receive similar benefits compared to
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APOE3 carriers and this should be considered when looking improve the gut
health of APOE4 carriers. Also in the gut microbiota, we found no notable
differences due to the FAD mutations in either E3FAD or E4FAD despite other
studies indicating that these mutations increased amyloid-like proteins in the gut
[40] and impacted amyloid deposition in the brain [41]. Notably, a slightly different
AD mouse model was used in these studies that involved just the APP and PS1
mutations and at different ages than our study. While it is still certainly possible
that the APOE4 allele provides protection against enteric infection and certain
FAD mutations alter the gut microbiota, we cannot confirm such effects.
One important aspect of the gut microbiota is how much of the benefits
actually make it to the periphery and play a role on the host. In our project, we
see that scyllo-inositol, SCFAs, and even IPA are increased due to the prebiotic
inulin in the blood. However, E4FAD mice saw little scyllo-inositol in the blood in
either the prebiotic or control group. Nevertheless, this is a landmark finding as
inulin is seen here to increase multiple GBA components and we are able to
declare scyllo-inositol a GBA component for the first time. Not only this but there
were many other metabolic differences that were altered due to the prebiotic
inulin in both E3FAD and E4FAD mice. There was an increase in tryptophan
metabolism and a decrease in tyrosine metabolism. While we cannot assuredly
say this will benefit the host, although the increase in the tryptophan metabolite
IPA may be beneficial due to its inhibitory effects on A aggregation [85], this is a
major finding in the prebiotic field. It would be of interest if these findings could be
repeated with other prebiotics. Also, in the blood, we also found differences in the
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PPP and TCA Cycle. While it is known that APOE4 carriers develop
hypometabolism and have altered glucose metabolism [228], the PPP has been
recently implicated [27] and may be a research avenue that needs more
exploring.
The next step in the project was to see if the effect of the prebiotic inulin in
the gut microbiota could not only reach the periphery but also the brain. Here we
do indeed see that scyllo-inositol was increased in the hippocampus of both
E3FAD and E4FAD mice fed the prebiotic inulin. Contrary to what you may think
due to the findings in Chapters 3 and 4 where greater increases in scyllo-inositol
in the gut and absorption thereof into the periphery were found in E3FAD mice
compared to E4FAD mice fed the prebiotic inulin, the E4FAD mice actually saw a
greater increase in hippocampal scyllo-inositol compared to E3FAD mice. This
indicates that E4FAD mice may have a compensatory effect, perhaps due to
increased inflammation in the brain, that enables more scyllo-inositol, which can
decrease inflammation via inhibition of A aggregation [165], to be brought into
the brain compared to E3FAD mice. Reasons how this occurs are not available
as scyllo-inositol is a little studied metabolite. It is also plausible that myo-inositol
could be converted to scyllo-inositol, or vice-versa in the blood and/or brain but
the only evidence of this is in the blood [161]. In this study, scyllo-inositol was
administered in the blood of mice with a subsequent increase seen in myoinositol levels. This evidence is not particularly strong, but the possibility still
remains.
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The next and final step was to see if the changes due to the prebiotic inulin
were able to not only reach the periphery and brain but to also decrease AD risk
factors and pathology. We did indeed see alterations in inflammation in mice fed
the prebiotic inulin, but many AD risk factors and pathology were not altered. This
included no differences seen in CBF, anxiety and cognition, and A aggregation.
Due to the increase in gut-brain axis components that have literature supporting
their ability to inhibit A aggregation, we suspected the prebiotic inulin may
indeed be able to decrease A. However, this was not the case. It is possible if
we began the prebiotic diet on the mice at an earlier age or fed them for a longer
period of time, then differences would become more evident. Nevertheless, we
did see a notable downward trend in inflammatory genes due to the prebiotic
inulin via a decrease in 52 genes that were increased by the FAD mutations.
Among these, CCL4 and Fcgr4 were significantly decreased while CXCL10 and
Itgax were insignificantly decreased. It is quite notable that these aforementioned
inflammatory markers have been associated with AD pathology and disease
progression. Due to this, we do indeed believe the consumption of the prebiotic
inulin may be a convenient, translatable way to decrease AD risk factors and
pathology over time.
Collectively, we see that the prebiotic inulin is able to increase numerous
components of the gut-brain axis that were able to reach the brain. In fact, a new
gut-brain axis component has been revealed in scyllo-inositol. A aggregation
and numerous AD risk factors were unable to be impacted by the prebiotic inulin,
however, markers of inflammation in the brain were decreased due to the
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prebiotic inulin. Overall, this research enables a paradigm shift as taking
preventative measures to decrease AD risk factors in APOE4 carriers may be
effective in helping to prevent the disease.
6.2

Limitations
A limitation of our project was the use of our animal model. Although we

believe that the EFAD mouse model is the most state-of-the-art and translatable
AD mouse model available, as it allows us to see AD pathology within just a few
months of age in the mice, AD mouse models have historically translated poorly
to clinical outcomes [229]. It also cannot be discounted that mice and humans
are different species that will vary in results.
A major limitation of Aim 1 involves the gut microbiota; however, this is the
same limitation present with gut microbiota research in general. Although the
method to extract DNA from the fecal sample appears to have minimal impact,
the varying techniques used to target the bacterial 16S rRNA gene of the mice
can impact the results and reproducibility in a major way [230]. Further, the
husbandry of the mice also varies and can impact results, among other
challenges [231]. In our study, the groups were split into two batches and thus, a
batch effect was present to where a direct comparison of E3FAD and E4FAD
mice became impossible. However, this will be considered in all our future
endeavors.
Another limitation related to the gut microbiota involves scyllo-inositol.
Bacillus subtilis is the only known bacterial taxa to increase this metabolite [155]
and we did not find this taxon in our 16S rRNA sequenced data. We do know that
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scyllo-inositol was increased due to our fecal bacterial culture experiment. Thus,
we believe that other bacterial species are also able to produce this metabolite
and identifying these taxa could be a future direction of our lab’s research.
In Aim 3, we found that the prebiotic inulin was unable to impact CBF and
animal behavior tests or decrease A aggregation. This may be due to stopping
the study before they reached an advanced enough age to develop deficits in
CBF and in animal behavior tests. Due to the E4FAD mice not having deficits in
CBF and in the animal behavior tests compared to E3FAD mice, we do indeed
suspect the mice at 7-months of age were not old enough to develop such
deficits. This may also be true in regard to the lack of decrease in A aggregation
in E4FAD mice fed the prebiotic inulin, however, we do not necessarily believe
that the amyloid cascade hypothesis, the hypothesis that A plaques are the
primary culprit for the disease, is solely responsible for AD [232]. Indeed, studies
have shown that normal cognitive people have amyloid plaques and that
decreasing these plaques in AD patients has no effect on their symptoms [232].
The amyloid cascade hypothesis has also consistently failed clinically to meet
primary endpoints although this may also be due to beginning treatment too late
in AD pathology [232, 233]. Nevertheless, we believe with the prebiotic inulin
able to decrease inflammation and alter the metabolism of E4FAD mice, utilizing
this nutritional intervention may be a paradigm shift in preventing AD.
And finally, the last notable limitation is that we did not look for
neurofibrillary tangles, one of the primary hallmarks of the disease and potential
causative agent of AD [234].
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6.3

Significance and Implications
This project has major significance and implications towards the future of

GBA and AD research. The findings from Aim 1 demonstrate that E3FAD and
E4FAD mice are both able to ferment the prebiotic inulin into beneficial
metabolites but in dissimilar amounts. Indeed, the E3FAD mice appear to get
more benefit from the prebiotic inulin than the E4FAD mice. This indicates that
the genetic makeup of an organism can impact the gut microbiota, their response
to prebiotics, and ability to ferment prebiotics into metabolites. This signifies that
personalizing treatments based on one’s genetics may be more effective in
preventing and treating AD compared to a standard approach.
Aim 2 is significant because we see that the metabolites produced from
the fermentation of the prebiotic inulin are indeed able to reach the bloodstream
and brain to potentially exert effects. Although prebiotics may be fermented by
the gut microbiota, their impact is exerted beyond into other organs. This may
pave the way for other interventions that benefit the gut microbiota to come into
the limelight, be moved into clinical trials, and eventually, used as a part of a
personalized AD prevention plan, especially for those that are genetically
predisposed to the disease. In this aim, we also see scyllo-inositol as a new,
novel component of the GBA. As more and more GBA components are revealed,
more treatment and prevention plan that look to benefit the GBA could be
utilized. We also saw the increase in SCFAs and IPA, known GBA components,
that provides compelling evidence that the prebiotic inulin can impact numerous
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GBA components. Interestingly, we also saw metabolic differences between
E3FAD and E4FAD mice in the blood and brain, indicating that the absorption of
metabolites from the gut and impact thereof in the periphery is also different
depending on one’s genetics.
Aim 3 is significant because we see that a nutritional intervention is able to
decrease AD risk factors via diminished inflammation. Due to pharmacological
interventions primarily failing [5], it has been suggested that preventative
measures may be more effective in preventing and treating AD [6]. Our results
confirm that a nutritional intervention such as prebiotics can be effective in
helping to decrease AD risk factors, signifying a paradigm shift in how we
approach AD care in human patients. Indeed, benefiting the gut microbiota and
GBA may be the first preventative measure that one should undertake to prevent
AD.

6.4

Future Directions
The future directions for this research are vast! Firstly, a better

understanding of what bacterial taxa produce certain metabolites would greatly
help us understand the gut microbiota and the benefits it can produce on the
host, including that of the taxa that produce scyllo-inositol. Next, using different
prebiotics, such as inulin, resistant starch and galacto-oligosaccharides, and
comparing the effects of these prebiotics to each other on the gut microbiota and
brain would greatly influence the literature and translatability to humans. It is
plausible that all prebiotics are able to increase the production of beneficial
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metabolites. However, it is also possible that only the prebiotic inulin is able to
increase scyllo-inositol while other prebiotics cannot produce scyllo-inositol but
can increase other, unique metabolites. Combining multiple prebiotics would be
very beneficial as well as the human diet would more likely contain a mixture of
different foods and prebiotics as opposed to specializing in the consumption of
just one. Subsequently, using different dosages of prebiotics and seeing if there
is a dose-dependent effect of benefits and metabolite production would also be
highly valuable. This could greatly impact how this research can be translated to
humans and what exactly humans should be consuming, and in what amounts,
for optimal gut microbiota and GBA health. Next, further understanding the
differences between APOE3 and APOE4 carriers would help in translating
findings to humans as a personalized approach may be more effective
depending on one’s genes in preventing and treating AD compared to a standard
treatment that doesn’t take this into account. However, to fully understand the
significance and implications of this project, studies in clinical trials looking at the
impact of the prebiotic inulin on the GBA and AD, in APOE3 and APOE4 carriers
alike, need to be completed.
The final notable future direction is to feed the mice for a longer period of
time and until the mice reach an older age. Considering there were no deficits in
CBF and animal behavior tests between E3FAD and E4FAD mice at 7-months of
age, it may be worth measuring these outcomes again when the mice reach 10
or 12-months of age and then seeing the impact of the prebiotic inulin on AD
pathology.
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[Supplement] Age Drives Distortion of Brain Metabolic,
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Lin
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7.1

Summary
Advancing age is the top risk factor for the development of

neurodegenerative disorders, including Alzheimer’s disease (AD). However, the
contribution of aging processes to AD etiology remains unclear. Emerging
evidence shows that reduced brain metabolic and vascular functions occur
decades before the onset of cognitive impairments, and these reductions are
highly associated with low-grade, chronic inflammation developed in the brain
over time. Interestingly, recent findings suggest that the gut microbiota may also
play a critical role in modulating immune responses in the brain via the brain-gut
axis. In this study, our goal was to identify associations between deleterious
changes in brain metabolism, cerebral blood flow, gut microbiome, and cognition
in aging, and potential implications for AD development. We conducted our study
with a group of young mice (5-6 months of age) and compared those to old mice
(18-20 months of age) by utilizing metabolic profiling, neuroimaging, gut
microbiome analysis, behavioral assessments, and biochemical assays. We
found that compared to young mice, old mice had significantly increased levels of
numerous amino acids and fatty acids that are highly associated with
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inflammation and AD biomarkers. In the gut microbiome analyses, we found that
old mice had increased Firmicutes/Bacteroidetes ratio and alpha diversity. We
also found impaired blood-brain barrier function and reduced cerebral blood flow
as well as compromised learning and memory and increased anxiety, clinical
symptoms often seen in AD patients, in old mice. Our study suggests that the
aging process involves deleterious changes in brain metabolic, vascular and
cognitive functions, and gut microbiome structure and diversity, all which may
lead to inflammation and thus increase the risk for AD. Future studies conducting
comprehensive and integrative characterization of brain aging, including
crosstalk with peripheral systems and factors, will be necessary to define the
mechanisms underlying the shift from normal aging to pathological processes in
the etiology of AD.

7.2

Introduction
Advancing age increases the risk factor for developing dementia, with

imaging and biomarker data suggesting that the pathophysiological processes of
Alzheimer’s disease (AD) begin more than a decade prior to the diagnosis of
dementia [23, 235-237]. However, how aging processes contribute to AD etiology
still remains unclear. Bioenergetic imbalance over time has been considered as
one of the primary causes for these chronic disorders [238]. In the central
nervous system, brain energy supply declines with age [239]. Failure to maintain
brain metabolism causes dysfunctional cellular energy status and nucleotide
biosynthesis [240], leading to cognitive impairment and brain volume atrophy
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[241]. In addition, this energetic imbalance leads to neuroinflammation
accompanied by reduced neuronal activity and increased glial activation [242245]. Glial over-activation can cause release of inducible nitric oxide synthase
(iNOS), which can result in inflammation and sepsis [246]. Chronic
neuroinflammation can further lead to retention of amyloid beta (Aβ) plaques and
tau tangles as seen in AD, and ultimately, memory loss, and dementia [224].
Emerging evidence shows the metabolic imbalance and inflammatory
responses may not only originate in the brain per se, but also from gut microbiota
[247]. The gut microbiota is the community of microorganisms in the intestines
that contains over 1,000 different bacterial species, categorized into four primary
phyla: Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria [248]. A
number of studies have demonstrated that the gut microbiota changes with age
[249-251]. In particular, an increased Firmicutes/Bacteroidetes (F/B) ratio is
associated with increased inflammation and excess energy harvest from food in
obese patients [252]. Increased F/B ratio is associated with the weakening of the
epithelial tight junctions, allowing proinflammatory cytokines produced by
pathogenic bacteria transfer to the brain from the blood stream or vagus nerve
[72, 253]. Inflammation due to leaky gut syndrome has also been shown to
increase the risk for anxiety and depression [254], which can exacerbate learning
and memory performance [255, 256].
Leaky gut syndrome also leads to neurovascular defects, evident by
increased blood-brain barrier (BBB) permeability [72]. The reduction of BBB
transporters may lead to impaired clearance of Aβ [20, 237], enhancing the risk
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of dementia like symptoms [257]. Impaired BBB function is also linked with
reduced cerebral blood flow (CBF) [20]. Indeed, reductions in CBF with age have
been known for years [212]. These neurovascular risks are highly associated
with accelerated decline in language ability, verbal memory, attention and
visuospatial abilities, and increased anxiety and depression in aging [236, 237,
258-260].
Collectively, the cognitive aging and risk for AD may be driven by
deleterious changes of brain physiology originated from the central nervous
system as well as the peripheral systems. Nonetheless, the associations
between brain metabolism, perfusion, cognition, and gut microbiome remain
largely unknown. In this study, our objective was to examine the effects of aging
on the brain and the gut in young and old mice and how these effects collectively
alter neurological function. To achieve this, we used metabolomics for brain
metabolite assessment, 16s ribosomal RNA (rRNA) gene amplicon sequencing
to analyze the gut microbiome, neuroimaging to examine brain vascular
functions, and behavioral testing to determine memory and anxiety. We
hypothesized that age-related deleterious changes would be exhibited in the
brain and gut, effecting brain metabolic, vascular and cognitive functions, which
may increase the risk for developing AD.
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7.3

Methods

7.3.1 Animals
Young (5-6 mo) and old (18-20 mo) male C57BL/6N mice were acquired
from the National Institute of Aging Colony. We determined the sample size via
power analysis to ensure comparison at a 0.05 level of significance and 90%
chance of detecting a true difference of each measured variable between the two
groups. Each mouse was caged individually and housed in a specific pathogenfree facility. In order to avoid the potential for aggression when combining
multiple male mice into one cage, mice were housed individually. Further, mice
should be housed individually for gut microbiome analysis due to cage effects
from microbiome transfer, e.g. mice eating each other’s feces giving them a very
similar gut microbiome and thus, the mice would be N = 1 for that particular cage
[113]. The mice were weighed weekly and given ad libitum access to food and
water. All experimental procedures were performed according to NIH guidelines
and approved by the Institutional Animal Care and Use Committee (IACUC) at
the University of Kentucky (UK).

7.3.2 Gut Microbiome Analysis
For fecal DNA amplification, fecal samples were collected from young (N
=39) and old (N= 28) mice and frozen at -80˚C until further use. A PowerSoil
DNA Isolation Kit (MO BIO Laboratories, Inc.) was used for fecal DNA extraction,
according to the manufacturer’s protocol. Genomic DNA was PCR amplified with
primers CS1_515F and CS2_926R [114] targeting the V4-V5 regions of microbial
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16S rRNA genes using a two-stage “targeted amplicon sequencing (TAS)”
protocol [115, 116]. First stage amplifications were performed with the following
thermocycling conditions: 95˚C for 3mins, 28 cycles of 95˚C for 45sec, 55˚C for
45sec, 72˚C for 90sec and final elongation at 72˚C for 10 minutes. Barcoding
was performed using a second-stage PCR amplification with Access Array
Barcode Library for Illumina Sequencers (Fluidigm, South San Francisco, CA;
Item# 100-4876). The pooled libraries, with a 15% phiX spike-in, were loaded on
a MiSeq v3 flow cell, and sequenced using an Illumina MiSeq sequencer, with
paired-end 300 base reads. Fluidigm sequencing primers, targeting the CS1 and
CS2 linker regions, were used to initiate sequencing. De-multiplexing of reads
was performed on instrument. Second stage PCR amplification and library
pooling was performed at the DNA Services (DNAS) facility, Research
Resources Center (RRC), University of Illinois at Chicago (UIC). Sequencing was
performed at the W.M. Keck Center for Comparative and Functional Genomics at
the University of Illinois at Urbana-Champaign (UIUC).
For microbial analysis, forward and reverse reads were merged using
PEAR [117]. Primer sequences were identified using Smith-Watermann
alignment and trimmed from the sequence. Reads that lacked either primer
sequence were discarded. Sequences were then trimmed based on quality
scores using a modified Mott algorithm with PHRED quality threshold of p = 0.01,
and sequences shorter than 300 bases after trimming were discarded. QIIME
v1.8 was used to generate OTU tables and taxonomic summaries [118]. Briefly,
the resulting sequence files were merged with sample information. Operational
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taxonomic unit (OTU) clusters were generated in a de novo manner using the
UCLUST algorithm with a 97% similarity threshold [119]. Chimeric sequences
were identified using the USEARCH61 algorithm with the GreenGenes 13_8
reference sequences [120]. Taxonomic annotations for each OTU were using the
UCLUST algorithm and GreenGenes 13_8 reference with a minimum similarity
threshold of 90% [119, 120]. Taxonomic and OTU abundance data were merged
into a single OTU table and summaries of absolute abundances of taxa were
generated for all phyla, classes, orders, families, genera, and species present in
the dataset. The taxonomic summary tables were then rarefied to a depth of
10,000 counts per sample.
Shannon and Bray-Curtis indices were calculated with default parameters
in R using the vegan library [121, 122]. The rarefied species data, taxonomic
level 7, were used to calculated both indices. Plots were generated in R using
the ggplot2 library [123]. Significant difference among tested groups was
determined using the Kruskal-Wallis one-way analysis of variance. The group
significance tests were performed on the rarefied species data, taxonomic level 6
(genus), using the group_significance.py script within the QIIME v1.8 package.
The gene amplicon sequence data generated as part of this study have
been submitted to the NCBI BioProject database under accession number
(PRJNA400638).
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7.3.3 Behavior Testing
All behavior tests were conducted over a two-week period with each test
starting at the same time each morning. For each mouse, Elevated Plus Maze
(EPM) was done first followed by Novel Object Recognition (NOR) the next day.
Radial Arm Water Maze (RAWM) testing was then carried out starting the day
after NOR. A subset of young (N = 22) and old (N =18) mice underwent three
behavior tests. For more details on the three behavior tests, please see Chapter
2, section 2.9.

7.3.4 Cerebral Blood Flow Measurement
A subset of young and old mice (N = 12 per group) were used to measure
in vivo CBF using magnetic resonance imaging (MRI). For more details on this,
please see Chapter 2, section 2.6.

7.3.5 Blood-Brain Barrier Function Determination and Western Blotting
BBB function was determined by measuring P-glycoprotein (P-gp)
transport activity in isolated brain capillaries. P-gp is an ATP-driven transporter
highly expressed at the BBB that facilitates transport of Aβ from brain to blood.
This technique was previously established via a confocal imaging-based assay to
assess P-gp transport activity in freshly isolated brain capillaries from mice [261,
262]. This assay measures within capillary lumens accumulation of [N-ε(4-nitrobenzofurazan-7-yl)-D-Lys(8)]-cyclosporin A (NBD-CSA), a fluorescent Pglycoprotein substrate.
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For capillary isolation, after euthanasia, mouse brain capillaries (N= 7 per
group) were isolated according to a previously described protocol [261, 263].
Briefly, mice were euthanized by CO2 inhalation and decapitated; brains were
immediately harvested and collected in ice-cold DPBS buffer supplemented with
5 mM D-glucose and 1 mM Na-pyruvate, pH 7.4. Brains were dissected by
removing meninges, choroid plexus and white matter, and homogenized in
DPBS. The brain homogenate was mixed with Ficoll® and centrifuged at 5,800g
for 20 minutes at 4°C. The capillary pellet was resuspended in 1% BSA buffer
and first passed through a 300 µm nylon mesh and then through a 27 µm nylon
mesh. Capillaries retained by the 27 µm nylon mesh were collected and washed
with DPBS buffer and used for experiments.
For p-glycoprotein transport activity, isolated capillaries were incubated for
1 h at room temperature with 2 μM NBD-CSA (custom-synthesized by R. Wenger
(Basel, Switzerland)) in DPBS buffer. Ten capillary images were acquired by
confocal microscopy (Leica TSP SP5 Confocal Microscope with Environmental
Chamber, 63 × D-Water UV objective, numerical aperture 1.2, Zoom: 4, 488-nm
line of an argon laser, Leica Microsystems). Confocal images were analyzed by
quantitating luminal NBD-CSA fluorescence with Image J software (v.1.45s;
Wayne Rasband, NIH). Specific, luminal NBD-CSA fluorescence was taken as
the difference between total luminal fluorescence and fluorescence in the
presence of the P-glycoprotein-specific inhibitor PSC833 (5 μM, Novartis, Basel,
Switzerland) [264].
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For western blotting and quantification to determine protein expression,
isolated brain capillaries were homogenized in tissue lysis buffer containing a
cocktail of protease inhibitors. Homogenized brain capillary samples were
centrifuged at 10,000 g for 15 minutes at 4°C, followed by a centrifugation of the
denucleated supernatants at 100,000 g for 90 minutes at 4°C. Pellets (crude
brain capillary plasma membranes) were resuspended and protein
concentrations were determined using the Bradford protein assay. Normalized
brain capillary membrane samples were separated on a NuPAGE™ 4-12% BisTris Protein Gels (1.0 mm, 15-wells; Thermo Fisher Scientific, Waltham, MA,
USA) and transferred onto an Invitrolon™ PVDF membrane (0.45 µm pore size;
Thermo Fisher Scientific, Waltham, MA, USA) membrane using the NuPAGE ®
electrophoresis and blotting system (Invitrogen, Carlsbad, CA, USA). After
protein transfer, the blotting membranes were incubated overnight with antibody
to P-gp (C219; MA1-26528, ThermoFisher, 1μg/ml) and β-actin (ab8226 from
Abcam, 1:1000, 1 μg/ml). Proteins were detected using SuperSignal® West Pico
Chemoluminescent substrate (Pierce, Rockford, IL, USA) and protein bands
were visualized with a BioRad Gel Doc™ XRS imaging system. P-gp was
visualized first, membranes were then stripped with Restore™ Western Blot
Stripping Buffer (Thermo Fisher Scientific, Waltham, MA, USA) and incubated
with the antibody against β-actin. Image Lab 5.0 software from Bio-Rad
Laboratories was used for densitometric analyses of band intensities and digital
molecular weight analyses; the molecular weight marker was RPN800E (GE
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Healthcare, Chalfont St. Giles, Buckinghamshire, UK). Linear adjustments of
contrast and brightness were applied to entire Western blot images.

7.3.6 Inducible Nitric-Oxide Synthase Measurement
Total RNA from frontal cortex and hypothalamus homogenate (N =7-8 per
group) was isolated using TRI Reagent solution (Ambion), and cDNA was
synthesized from 1ug total RNA from each individual sample using SuperScript
III (Invitrogen). qRT-PCR was performed using TaqMan real time PCR (ViiA™ 7,
Applied Biosystems). All reactions were performed with non-template negative
control, and all data are mean ± SEM of two independent biological replicates.
The gene probes and master mix were also purchased from Applied Biosystems.
The probe sets were as follows: Mm00440502-m1 (inducible nitric-oxide
synthase (Nos2)), Mm00446968-m1 (hypoxanthine guanine phosphoribosyl
transferase (Hprt)). The relative expression levels were measured using the
relative quantitation ΔCt (delta counts) method and normalized to Hprt.

7.3.7 Metabolomic Profiling
Please see Chapter 2, section 2.5 for more detail.

7.3.8 Statistical Analysis
All statistical analyses were completed using GraphPad Prism (GraphPad,
San Diego, CA, USA). One-tailed Student’s t-test was performed for
determination of differences between groups. Levels of statistical significance
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were reached when p < 0.05. For Metabolon, missing values in the data are
assumed to be below the level of detection of the used instruments. Log
transformations and imputation of missing values with the minimum observed
values for each metabolite was conducted. This was followed by ANOVA to
identify biochemicals that were significantly different between groups. Given the
multiple comparisons inherent in analysis of metabolites, between-group relative
differences are assessed using both p-value and false discovery rate analysis (qvalue).
7.4

Results

7.4.1 Altered Gut Microbiome and Increased Body Weight with Age
Alpha diversity (e.g., Shannon index, H value) was measured for fecal
microbial communities of all samples, at the taxonomic level of genus (Figure
1A). Older mice had a significantly higher alpha diversity than young mice
(Kruskal-Wallis p-value = 0.022). Although no significant differences in beta
diversity were observed (Analysis of similarity, ANOSIM R statistic=0.006, pvalue=0.307, 999 permutations), and no specific taxa were significantly different
between the groups of young and old mice (Kruskal-Wallis, false discovery rate,
FDR-corrected p-value <0.05), the ratio of Firmicutes/Bacteroidetes was
significantly different between age groups. Old mice had significantly higher
Firmicutes/Bacteroidetes (F/B) ratio (Fig. 1B, 46% increase, p < 0.05). Further,
we found that the body weight of the old mice was significantly higher compared
with that of the young mice (Fig. 1C, 24% increase, p < 0.05).
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7.4.2 Enhanced Proinflammatory Metabolism with Age
The quantification of the brain metabolites is shown in Table 7.1. We
observed several significant age-dependent changes in basal brain metabolites
(after 6 hours of final feeding). Notably, the old group had a 31-83% change in
markers of the methionine cycle with significantly greater methionine, cysteine,
cysteine-glutathione disulfide, and cystathionine. Firstly, methionine is an amino
acid that may be accountable for increased mitochondrial reactive oxygen
species (ROS)[265]. Due to this, we believe the old mice exhibit increased
oxidative stress in the brain. We also found lipids related to inflammatory
responses significantly elevated in the old mice, including a 82% increase in
prostaglandin D2, and a 80% increase in prostaglandin E2. Further, markers
associated with Alzheimer’s disease (AD) were significantly greater in the old
mice compared to the young, including a 21% increase in 24(S)hydroxycholesterol, 28% increase in mead acid (20:3n9), 37% increase in
phenylalanine, 58% increase in spermidine, 22% increase in docosapentaenoate
(n6 DPA; 22:5n6), 11% increase in creatine, and 12% increase in
phosphocholine [266-272]. In contrast, CDP-choline, a metabolite that has shown
to alleviate AD symptoms [273], saw a 6% decrease in the old group. In addition,
old mice also demonstrated a 114% increase in citrate. Collectively, the
metabolic profiling indicates that the old mice had enhanced proinflammatory
metabolism. These data are consistent with our observation of significantly
increased iNOS levels in the brain of old mice compared to that of young mice
(Fig. 2A, 17% increase, p = 0.02).
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We found that two of the brain metabolites related to gut microbiota were
also significantly different between young and old cohorts. Compared to the
young mice, old mice had significantly higher 3-indoxyl sulfate (Fig. 2B, 380%
increase, p < 0.05) and phenol sulfate (Fig. 2C, 144% increase, p < 0.05) in their
brain within 2 hours after their final feeding, however, the levels of the two
metabolites returned to the baseline after 6 hours of feeding. 3-indoxyl sulfate is
generated in the liver as a result of gut microbiome metabolism of tryptophan;
phenol sulfate is a metabolite derived from bacterial metabolism of
phenylalanine. The results suggest that the gut microbiome may play an
important role in modulating brain metabolism. Because 3-indoxyl sulfate and
phenol sulfate both are related to neurological toxicity and inflammation [274,
275], it implies that old mice had higher neuroinflammation, which may of
resulted from age-dependent changes in the gut microbiota.

7.4.3 Impaired Neurovascular Functions with Age
We found impaired BBB function in the old mice. Figure 3A shows
representative confocal images of capillaries; the intensity of fluorescence in the
capillary lumen reflects the amount of P-glycoprotein (P-gp), an efflux transporter
of A. The corresponding quantitative results are shown in Figure 3B; the old
mice had significantly reduced P-gp transport activity (p = 0.0031) compared to
the young mice. We also measured P-gp protein expression levels (Fig. 3C).
Similar to the results of P-gp activity, we found that the old mice had significant
reduction in P-gp protein levels compared to the young mice (decrease to 63.7 ±
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5.4 % over 100% young; p < 0.001; Fig. 3C). We also observed reduced CBF in
the old mice. Figure 3D shows the representative CBF images of the young and
old mice. The CBF level is colorized in a linear scale, indicating that the young
mice have overall higher CBF compared to the old mice, which was confirmed by
the quantitative global CBF values (Fig. 3E, 87% increase, p < 0.001). We did
further CBF analyses in brain regions associated with cognitive functions (e.g.,
memory and learning) based on MRI structural imaging and mouse brain atlas.
We found that young mice exhibited an 82% increase in CBF in the hippocampus
(p < 0.001, Fig. 3F), compared to the old mice.

7.4.4 Compromised Cognition and Increased Anxiety with Age
The old mice spent significantly longer time in the closed arms compared
to the young mice in the EPM test (Fig. 4A; 132% increase, p < 0.0001),
indicating higher anxiety. In the NOR test, the old mice showed a significantly
lower D2 value compared to the young group, suggesting reduced recognition
memory (Fig. 4B, -74% decrease, p < 0.0001). In the RAWM test, the old group
made significantly more errors in the learning phase (Block 3; 46% increase, p <
0.01) and the initial recall phase (Block 4; 43% increase, p < 0.01), compared to
the young group (Fig. 4C).

7.5

Discussion
In this study, we demonstrated the age-dependent changes in brain

metabolism, gut microbiome, vascular functions, memory and anxiety.
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Specifically, aged mice had enhanced proinflammatory, increased ratio of
Firmicutes to Bacteroidetes, increased bacterial alpha diversity, and body weight,
impaired BBB and CBF, compromised learning and long-term memory, and
increased anxiety. These deleterious changes in aging have the potential to
increase the risk for neurological disorders and dementia, including AD.
We found several amino acid increased in the old mice that are highly
associated with AD, including spermidine, phenylalanine, creatine citrate, and
methionine-related metabolites. First, spermidine levels have been found to be
higher in the temporal cortex with a trending elevation in hippocampus and
frontal cortex in AD patients, potentially as a response to brain injury [269].
Excess spermidine could exacerbate neurodegeneration as it positively
modulates N-methyl-D-aspartate (NMDA) glutamate receptor function and disrupt
calcium homeostasis. Second, high phenylalanine levels are also found in AD
patients, associated with immune activation [268]. Phenylalanine disturbs
neopterin and tryptophan metabolism, which is correlated with cognitive
impairment [276, 277]. Third, old mice had higher creatine deposits in the brain,
consistent with literature that creatine metabolism malfunction plays an important
role in AD [237, 271]. Fourth, old mice had increased levels of citrate in the brain
suggesting increased usage of fatty acid synthesis for membrane remodeling
associated with aging due to the increased stress and inflammation that damage
neuronal membranes [278]. Finally, the old mice had altered methionineassociated metabolism, including increased methionine, cystathionine, cysteine,
and cysteine-glutathione disulfide. Excessive methionine has been considered to
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be accountable for increased mitochondrial ROS production, which in turn
enhances oxidative stress and inflammation [277, 279, 280]. Interestingly,
previous studies have shown that methionine restriction can lead to increased
longevity by decreasing mitochondrial complex IV activity and accumulation of
ROS [281, 282].
Accumulation of lipids in the brain is another hallmark of AD [283]. In the
present study, we also found AD-associated fatty acids increased in the aged
mice. First, 24(S)-hydroxycholesterol, an oxidized product of cholesterol
produced in the brain, has been demonstrated to be elevated in AD patients and
is hypothesized to be an early marker for distorted cholesterol status [266].
Second, phosphocholine has been revealed to be increased in rats during the
early stages of AD during lesion-induced neuronal sprouting in the hippocampus
[272]. This indicates that sprouting may occur early on in AD with
phosphocholine as a marker. In addition, sprouting may also lead to a decline in
energy metabolism due to energy being used for sprouting, consistent with the
evidence of glucose metabolism decline in AD. Third, mead acid (20:3n9), an
omega-9 fatty acid, has been demonstrated to be increased in the mid-frontal
cortex, temporal cortex, and hippocampus of AD patients [267]. Fourth,
docosapentaenoate (n6 DPA), an omega-6 fatty acid, has been inversely
correlated with learning [270]. This is consistent with previous findings that oleic
acid-enriched triglycerides were found in the brain of a triple transgenic mice
model of AD (3xTg-AD); but when the triglycerides were inhibited, proper brain
function was restored [284]. Further, prostaglandin D2 and E2, produced from
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arachidonate, are generators of an inflammatory response and present in
increased amounts in such an event, were also elevated in the old group [285].
Specifically, in one study, prostaglandin E2 was associated with neuronal
oxidative damage after activation by lipopolysaccharide (LPS)[286]. LPS also can
activate iNOS, which is consistent with our finding that old mice had significantly
increased iNOS expression in the brain. In contrast, the aged mice showed
reduced levels of CDP-choline, which has shown to alleviate AD symptoms by
increasing CBF and brain electrical activity and reducing serum cytokine IL-1β
levels [273]. Old mice also had dramatically decreased levels of
glycerophopshorylcholine (GPC), which has been used to treat patients with
cognitive impairment and AD [287]. Collectively, old mice exhibited a myriad of
markers associated with inflammation and AD.
The enhanced inflammation with age may have also occurred in the gut.
We found that 3-indoxyl sulfate and phenol sulfate, which originate from the gut
microbiota, were significantly elevated in the aged mice’s brains after meals.
Significant increases of indoxyl sulfate have shown to enhance neurological
toxicity, increase oxidative stress and ROS, and induce endothelial dysfunction
by inhibiting endothelial proliferation and migration in vitro [288, 289]. In addition,
phenol sulfate is derived from bacterial metabolism of phenylalanine, a marker
for AD, as mentioned above. Next, we found a modest increase in older mice in
the relative abundance of sequences from bacteria of the phylum Firmicutes, with
a concomitant decrease in the relative abundance of sequences from bacteria of
the phylum Bacteroidetes. Although neither change was statistically significant,
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the overall change, leading to an increased Firmicutes/Bacteroidetes (F/B) ratio
in older mice, was significant. As bacteria from the Firmicutes have been
associated with weight-gain and those within the Bacteroidetes with weight-loss,
this increased F/B ratio may promote body weight gain in old mice [49]. Further,
this increased F/B ratio may lead to excessive low-grade inflammation and a
substantial increase in energy harvesting and food intake [43, 290]. As a result,
the F/B ratio has become a well-known marker for obesity and T2DM (Type 2
Diabetes Mellitus) [291]. Interestingly, AD has been called Type 3 diabetes due
to the overlapping symptoms observed in T2DM, e.g. insulin resistance and
increased inflammation in the brain [292], along with an increased risk of
dementia [293]. Thus, the increased F/B ratio may be indicative of an increased
risk for AD.
Short-chain fatty acids (SCFAs), including butyrate and propionate that
are produced by certain bacterial species, have a dramatic impact on brain
function. For example, butyrate has been demonstrated to prevent inflammatory
responses via NFκB inhibition in microglia and hippocampal slice cultures [81].
Also, indole-3-proprionic acid (IPA), another metabolite produced by the gut
microbiome, was demonstrated to inhibit A fibril formation in neurons and
neuroblastoma cells [85]. On the contrary, increased Firmicutes may enhance
trimethylamine (TMA) and its co-metabolites trimethylamine N-oxide (TMAO)
[294]. TMAO level predicts risk for atherosclerosis and directly induces
cardiovascular disease [80, 295-297].
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Reduced SCFAs has been shown to induce BBB permeability [72]. This is
consistent with our findings that BBB function was compromised in the old mice.
Specifically, we found the old mice had a significantly lower quantity of P-gp
transporters in BBB, which are responsible for Aβ clearance from the brain to
blood, indicative of an increased risk of developing AD [298]. BBB breakdown
has been caused by elevated neuroinflammation [20] and is associated with CBF
reduction. In line with this, we found decreased CBF in old mice. In particular, old
mice had significantly decreased CBF in the hippocampus, the brain region that
modulates cognitive function. Further, the old mice performed worse in the
RAWM and NOR behavior tests than the young animals. Specifically, the old
group performed worse in Block 3 and 4 of the RAWM compared to the young
group, exhibiting inhibited spatial learning and long-term memory formation,
consistent with our previous findings [129, 133]. In the NOR test, the old group
had a worse D2 score compared to the young group, indicating a worse
recognition memory. Taken together, our findings are consistent with the
literature where impaired neurovascular integrity plays a critical role in
determining cognitive functions [299].
Higher anxiety levels were shown in old mice compared to young mice,
which may be also associated with brain vascular and metabolic dysfunctions
[258-260]. Interestingly, the gut microbiome has been linked with anxiety [141].
Indeed, the gut and brain are connected via the enteric nervous system and have
bi-directional communication, impacting behavior [300]. Certain bacterial species
such as L. rhamnosus have been demonstrated to decrease anxiety like
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symptoms and stress induced hormones [88]. Studies using oral administration
of food-borne pathogens showed evidence that bacteria residing in the
gastrointestinal tract can activate stress circuits through activation of vagal
pathways [301, 302]. Exposure to a subpathogenic infection of C. jejuni
increased anxiety-like behavioral measure in the EPM two days after infection
[303]. These studies clearly demonstrated that inflammatory state could have
strong influences on behavior and mental health. Conversely, treating mice with
probiotics has been shown to reduce anxiety-like behavior; the probiotic-treated
group showed increased entries into the open arms of the EPM compared to the
control group [304]. Further confirming the importance of the gut microbiome in
relation to stress, one study demonstrated germ-free mice to have an excessive
release of stress hormones. However, when these mice were colonized with
Bifidobacterium infantis, this response was alleviated [305]. Similar observations
were also made in clinical trials in patients with chronic fatigue, showing that
anxiety-like symptoms were alleviated by probiotics [306]. The study findings
may be applicable to AD as increased anxiety levels and depression are
commonly found preceding the onset of AD [225]. Modulating the gut microbiome
may thus be important for reducing risk or preventing AD and other
neurodegenerative disorders [307-310].
We summarize our findings with Figure 5. It shows that advancing age
drives deleterious modifications in metabolism, gut microbiome, neurovascular
integrity, cognition, and mental health, which may significantly enhance the risk
for AD. Our study implies that inflammation may play a critical role in the
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remodeling process. This is consistent with the concept of inflammaging, the
phenomenon where innate immunity is activated, coupled with the rise of
proinflammation with advancing age [311]. We suggest that, based on our
results, the inflammatory responses with age are systematic; they may be
originated from the CNS as well as the peripheral systems, e.g., from the gut. To
promote healthy aging and prevent AD, it will thus be critical to manage lowgrade, chronic proinflammation over time.
In future studies, it is important to determine mechanisms linking the brain
and gut in the context of brain aging, including pathways involved in SCFAs,
neurotransmitters, vagus nerve activity, and immune system function. As well as,
to identify potential nutritional interventions that can promote brain-gut
interactions, such as probiotics and prebiotics.
We have recently shown that dietary interventions can delay brain aging
(e.g., caloric restriction and rapamycin) and thus, it will be crucial in the future to
determine if these dietary interventions also have a significant impact on the
brain-gut axis [129, 133, 312]. In addition, it will be imperative to develop
surrogate biomarkers using neuroimaging. In the present study, we used MRI to
measure in vivo CBF, but we have also developed imaging methods to determine
brain metabolic and anatomical integrity [313, 314]. Further, we will also use this
state-of-the-art technology to study brain-gut axis and make our research
strategy translatable to clinical applications.
In conclusion, we found the inflammation-associated impact on brain
metabolism, gut microbiome, neurovascular functions, memory, and anxiety in
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aging mice. However, additional research needs to be conducted on the gut
microbiome and mechanisms of the gut-brain axis. Understanding brain aging is
imperative to identify risks, and intervention thereof, for AD. A comprehensive
and integrative characterization of brain aging, including its crosstalk with
peripheral systems and factors, will help to define the mechanisms underlying the
shift from normal aging to pathological processes in the etiology of AD [309,
310].
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Table 7-1 Enhanced proinflammatory metabolism with age
Classification

Metabolite

P

Young

Old

Amino Acids

creatine

0.003

0.990 ± 0.022

1.101 ± 0.017

cystathionine

0.026

0.943 ± 0.072

1.316 ± 0.174

cysteine

0.007

1.023 ± 0.138

1.873 ± 0.262

cysteine-glutathione disulfide

0.013

1.008 ± 0.132

1.736 ± 0.267

methionine

0.001

0.915 ± 0.047

1.204 ± 0.015

phenylalanine

0.002

0.917 ± 0.042

1.255 ± 0.085

spermidine

0.016

0.910 ± 0.059

1.436 ± 0.238

Cofactors & Vitamins

citrate

0.008

0.867 ± 0.099

1.860 ± 0.381

Lipids

24(S)-hydroxycholesterol

0.025

0.939 ± 0.027

1.135 ± 0.098

CDP-choline

0.037

1.002 ± 0.014

0.944 ± 0.028

docosapentaenoate (n6 DPA;
22:5n6)

0.007

0.994 ± 0.019

1.215 ± 0.085

mead acid (20:3n9)

0.025

1.070 ± 0.068

1.367 ± 0.122

phosphocholine

0.024

1.076 ±0.029

1.206 ± 0.054

prostaglandin D2

0.009

0.682 ± 0.087

1.238 ± 0.193

prostaglandin E2

0.007

0.746 ± 0.076

1.341 ± 0.207
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Table 7-1 Enhanced proinflammatory metabolism with age
Metabolomic profiling of brain metabolites. Representative data, shown in
scaled intensity, of the young and old groups. Data are mean ± SEM.
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Figure 7-1 Altered gut microbiome and increased body weight with age
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Figure 7-1 Altered gut microbiome and increased body weight with age
(A) The old mice showed a higher alpha-diversity, as indicated by the
Shannon index, than the young mice (p = 0.02). Compared with the young mice,
the old mice had significantly increased (B) Firmicutes/Bacteroidetes ratio and
(C) body weight. N= 39 and 28 for young and old mice, respectively. Data are
presented as mean ± SEM.
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Figure 7-2 Age increases inducible nitric oxide synthase (iNOS)
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Figure 7-2 Age increases inducible nitric oxide synthase (iNOS)
(A) The old mice had a significant increase in iNOS in the brain compared
to the young mice (N = 7-8 per group). The old mice had acute elevations (2
hours after feeding) in (B) 3-indoxyl sulfate and (C) phenol sulfate; those levels
returned to baseline in 4 hours (N = 6 and 4 for young and old mice,
respectively).
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Figure 7-3 Impaired neurovascular functions with age
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Figure 7-3 Impaired neurovascular functions with age
(A) Representative confocal images showing decreased luminal
accumulation of NBD-CSA fluorescence (green) in brain capillaries isolated from
the old mice compared to young mice, indicating reduced P-gp activity. (B)
Corresponding quantitative fluorescence data; images are shown in arbitrary
fluorescence units (scale 0-255). Data are mean ± SEM for 10 capillaries from
one preparation of 10 mice. (C) Western blotting (WB) for P-gp from the cortical
vasculature, β-Actin was used as loading control (top); corresponding values are
shown in the table (bottom). The WB data from the old mice were normalized to
β-Actin and compared to the young mice (100%), **p < 0.01. (D) CBF maps
superimposed on structural images; the color code indicates the level of CBF in a
linear scale. Quantitative CBF (ml/g/min) obtained from (E) the whole brain and
(F) hippocampus (N = 12 per group). Data are mean ± SEM.
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Figure 7-4 Compromised cognition and increased anxiety with age
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Figure 7-4 Compromised cognition and increased anxiety with age
(A) The elevated plus maze found the old mice to have a significantly higher
closed arm duration compared to the young group. (B) The novel object
recognition test found the old group had a significantly lower recognition index, or
D2, than the young group. (C) The average errors made by the young and old
mice during the radial arm water maze split into 6 blocks. The significant
difference between the two groups in average errors corrected showing in Block
3 (p = 0.0307) and Block 4 (p = 0.0045). N = 22 and 18 for young and old mice,
respectively. Data are presented as mean ± SEM.

161

Figure 7-5 Association of age-dependent changes
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Figure 7-5 Association of age-dependent changes
Proposed associations of age-dependent changes in brain metabolism,
vascular integrity, gut microbiome, cognition and anxiety levels. Inflammation in
aging, or inflammaging, might play a critical role in be a driving the deleterious
changes in the brain and gut.
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